KINIT SERVICES CUSTOMER INFORMATION PACKAGE

KINET IS THE WORLD'S FIRST INTERNET ACCESSIBLE SUBSCRIPTION PROTEOMICS DATABASE OF ITS KIND WITH BUILT IN BIOINFORMATICS SEARCHING CAPABILITIES TO ASSIST CLIENTS IN THEIR CELL SIGNALLING RESEARCH. KINET FEATURES OVER 250,000 MEASUREMENTS OF THE EXPRESSION LEVELS AND PHOSPHORYLATION STATES OF HUNDREDS OF SIGNAL TRANSDUCTION PROTEINS FROM OVER 6000 KINETWORKS™ MULTI-IMMUNOBLOTS OF HUNDREDS OF DIFFERENT CELL AND TISSUE LYSATES.



This information Package has been designed to assist you in using our KiNET quantitative functional proteomics databank. Access to mouse control data is free. Full and unlimited access requires an annual subscription. If after reviewing this information you have any questions about KiNET, please contact our Technical Service Representatives by calling toll free in North America 1-866-KINEXUS or (604) 323-2547 Extension 1 or by e-mail at "info@kinexus.ca". This information is regularly updated and available from our website



KINET DATABANK INTRODUCTION

KiNET is the first Internet accessible subscription proteomics database of its kind. This powerful tool has built in bioinformatics searching capabilities for cell signalling research. Presently KiNET features over 200,000 measurements of the expression and phosphorylation states of hundreds of signal transduction proteins from over 6000 multi-immunoblots blots performed with control and treated tissue/cell samples. This highly unique data set has been generated in-house over the last 8 years by Kinexus in part through our Kinetworks™ immunoblotting services. Over 95% of the data in KiNET is unpublished and not available elsewhere.

KiNET empowers subscribers to generate data tables that are tailored to their specific cell signalling research questions. KiNET can be queried for the regulation of a target protein in hundreds of well defined experimental model systems. Alternatively, a tissue, cell line or specific treatment can be interrogated for changes in the expression and phosphorylation of hundreds of different proteins. All of the protein measurements deposited in KiNET were generated with the top 20% of over 3000 commercial antibodies that were independently tested and validated by Kinexus. Since all of the KiNET data was produced with the same reagents, methodology and equipment by our highly experienced scientists and technicians, the results are highly comparable.

With the availability of KiNET, our Kinetworks[™] immunoblotting services have become even more powerful for cell signalling research, since our clients can now view their Kinetworks[™] results in a much broader context. Our clients can correlate changes that they observe in particular target proteins of interest in their experimental model systems with hundreds of other cells and tissues. KiNET is also a useful tool to plan out future Kinetworks[™] experiments to maximize the prospects of research success. Clients can preview the expression levels and phosphorylation states of specific proteins in similar experimental model systems to better select the subset of proteins they should investigate. KiNET may also be useful for validation of some of the findings from our Kinex[™] antibody microarray services.

At the academic individual user rate of US \$998, and the corporate individual user rate of US \$1998, an annual subscription to KiNET costs much less than most other databases that feature only annotated data from the published scientific literature. Site licenses for multi-users to KiNET are also available to companies. With an annual subscription, users have unlimited access to KiNET over the Internet. Furthermore, based on the annual accumulation of Kinetworks[™] data, we expect the KiNET databank to grow by at least 20% over the next year. Moreover, we will be adding additional special features and capabilities to KiNET in the near future. This will include data from our Kinex[™] antibody microarray services. We will also be launching our Knowledge Bank, which will include consolidated data from the scientific literature and Kinexus for detailed information about protein kinases, protein phosphatases and phospho-sites.

As a community service, Kinexus permits free access to all of the mouse control data contained within KiNET. To get started with KiNET, simply go to the following website link http://www.kinexus.ca/kinet and register as a free user. The free user access is an excellent opportunity for researchers to get a sense of how KiNET actually works and performs. For full access, follow the posted instructions and apply on-line at the KiNET site. Part of the requirement for full access is completion of a KiNET License Agreement, which is included with this KiNET Customer Information Package. The KiNET Users Guide is also appended to the end of this package. If you have any questions about this or any of our other proteomics services please contact our Technical Service representatives by calling free in North America 1-866-KINEXUS or 1-604-822-9963 or by e-mail at info@kinexus.ca.

We would like to acknowledge that the KiNET software has been under development in partnership with Visual Knowledge/Upstream Biosciences with the generous support of the National Research Council of Canada's Industrial Research Assistance Program.



KINETTM LICENSE AGREEMENT

12 Month Subscription

KINEXUS AGREEMENT NO.

This Subscription Agreement is entered into effective as of the Effective Date by and between Kinexus Corporation ("**Kinexus**"), a Canadian corporation with a principal place of business at Suite 1, 8755 Ash Street, Vancouver, British Columbia, Canada, V6P 6T3 **AND** the corporation or other entity ("**Customer**") having the following name and business or institution address:

RECITALS

WHEREAS, Customer desires to have access to the Kinexus proteomics database KiNET; and

WHEREAS, Kinexus desires to provide KiNET to the Customer subject to the terms and conditions of this Agreement;

THEREFORE, in consideration of the premises and covenants and agreements contained herein, and other good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, Kinexus and Customer agree as follows:

1. **DEFINITIONS**

- 1.1 <u>"Authorized Site</u>" means any academic, non-profit research institute, government agency, or corporate office and sites meeting the criteria for use from which the Customer will access and use KiNET, further set forth in Exhibit A.
- 1.2 <u>"Authorized User</u>" shall mean any employee of Customer listed in Exhibit A.
- 1.3 <u>"End User</u>" means an individual scientist who is working for or with a commercial organization of any kind ("Corporate End User"), or a self-contained unit within a University or public or government research institution performing non-commercial research and development activities ("Academic End User").
- 1.4 <u>"KiNET</u>" shall mean a unique, copyright-protected extensive gathering of information, technical data, know-how and/or content that is proprietary to Kinexus and the rendition of such into usable forms and formats and other components as provided by Kinexus, including software and database tools.
- 1.5 <u>"Database Tools"</u> shall mean Kinexus proprietary tools or any third-party product licensed to Kinexus which enables Kinexus to provide access of KiNET to Customer.
- 1.6 <u>"Internal Purposes"</u> means use by Customer, or research and development activities in collaboration with commercial or non-commercial Third Party entities, provided that in the case of a of a collaboration with a third- party commercial entity, said commercial entity is licensed to access KiNET.

- 1.7 <u>"Licensed Marks"</u> means those trademarks, trade names and/or service marks owned by Kinexus and associated with the subject matter of this Agreement, Such marks include but at not limited to Kinexus, KiNET, Kinetworks and Kinex.
- 1.8 <u>"Third Party"</u> means any person or entity other than Customer, Authorized User(s) or Kinexus.

2. LIMITED LICENSE GRANT

3. DELIVERY AND CONTRACT TERM

The Customer shall receive online access to KiNET upon receipt of payment in full along with completion of this Agreement and registration on-line at <u>www.kinexus.ca/kinet</u> (or any other site as may be changed from time to time). KiNET is regarded as being delivered when the fax or email has been released by Kinexus to the Customer and the successful transmission is confirmed by the fax or email sending report. Kinexus retains the right to change passwords on a regular or emergency basis. The Customer will be notified in the event the password requires modification.

4. **RESTRICTION ON USE**

- 4.1 Kinexus retains all rights, titles, and interest to KiNET.
- 4.2 The Customer shall not at any time:
 - 4.2.1 Sell, reproduce, disclose or otherwise make KiNET available to any Third Party, in whole or in part and in any form (electronic, magnetic, optical, paper or otherwise), without the express prior written consent of Kinexus.
 - 4.2.2 Use or permit the use, in whole or in part, of KiNET as a basis or a component of a database for a Third Party.
 - 4.2.3 Transfer, have transferred, or permit to be transferred, manually or electronically, in whole or in part, KiNET without the express prior written consent of Kinexus.
 - 4.2.4 Use KiNET on behalf of any Third Parties.
 - 4.2.5 Use KiNET for any purpose not contemplated by the terms of this Agreement.
- 4.3 Automatic or manual download, copying or reproduction of KiNET in whole or in part, is expressly prohibited.
- 4.4 Passwords are assigned to Authorized Users only and are not to be given to anyone else. An Authorized User may use the password to access KiNET from another location such as from home or when travelling, provided they advise Kinexus of the reason and change in their IP address.
- 4.5 Customer specifically acknowledges and agrees that each of the terms and conditions of this Section 4 are material and failure of Customer to comply with these terms and conditions shall constitute sufficient cause for Kinexus to terminate this Agreement immediately upon written notice.

4.6 <u>Feedback</u>. Customer agrees to provide feedback regarding the use of KiNET to the Kinexus Sales & Marketing staff by direct contact or by email at <u>sales@kinexus.ca</u> from time to time.

5. FEES

- 5.1 Kinexus will invoice Customer and the Customer shall pay a license fee for the initial term as a lump sum payment in the amount described on the KiNET Service Order Form. The fee for KiNET for a single academic user is US \$998 and for a single corporate user is US \$1996 and is non-refundable once access has been granted. To obtain a discount or promotion off the regular fees for KiNET, including discounts for multiple users, the KiNET Service Order form must reference an official quotation. Customer agrees that the fees set forth in the quotation shall be considered confidential information.
- 5.2 The fee for KiNET shall be due upon receipt of the invoice and includes all updates to the database as made from time to time. Kinexus is entitled to revise the amount of the license fee for respective extension periods, and will issue the invoice for the extension period 1 month prior to the expiry of the current 12 month terms. The amount is due upon receipt of invoice. If the Customer does not wish to subsequently renew their License Agreement, they can terminate the Agreement with notice to Kinexus prior to the expiration date set forth in Section 2, and their access to KiNET will terminate on same expiration date.

6. DISCLAIMER OF WARRANTY

KINET IS PROVIDED "*AS IS*" AND WITHOUT WARRANTY OF ANY KIND. KINEXUS DOES NOT WARRANT, GUARANTEE OR MAKE ANY REPRESENTATIONS REGARDING THE USE OF THE RESULTS OF KINET OR ANY ACCOMPANYING MATERIALS IN TERMS OF THE COMPLETENESS, CURRENTNESS OR ACCURACY OF ANY INFORMATION CONTAINED THEREIN, OR THAT THE USE OF KINET OR ANY MATERIALS WILL MEET INSTITUTION'S NEEDS OR THAT USE WILL BE UNINTERRUPTED OR ERROR FREE. KINEXUS DISCLAIMS ANY AND ALL WARRANTIES EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION, WARRANTIES, MERCHANTABILTY, FITNESS FOR A PARTICULAR PURPOSE, TITLE AND NON-INFRINGEMENT.

7. LIMITATION OF LIABILITY

IN NO EVENT WILL KINEXUS OR ITS DIRECTORS, OFFICERS, EMPLOYEES, OR AFFILIATES BE LIABLE FOR ANY CONSEQUENTIAL, INCIDIENTAL, OR INDIRECT DAMAGES (INCLUDING DAMAGES FOR LOSS OF BUSINESS PROFITS, BUSINESS INTERRUPTION, LOSS OF BUSINESS INFORMATION, AND THE LIKE) ARISING OUT OF THE USE OR THE INABILITY TO USE KINET, EVEN IF INSTITUITON OR AN AUTHORIZED REPRESENTATIVE HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. KINEXUS' ENTIRE LIABILITY TO INSTITUTION AND INSTITUTION'S EXCLUSIVE REMEDY REGARDING THIS AGREEMENT SHALL BE LIMTIED TO ONE DOLLAR (\$1.00).

8. COPYRIGHT: TRADEMARK LICENSE

- 8.1 <u>Ownership</u>. Customer acknowledges that Kinexus owns all rights, title and interest, including patent, copyright, trade secret, trade name, trademark and other proprietary rights, in and to KiNET, and any corrections, bug fixes, enhancements, updates or other modifications, including custom modifications, to KiNET, whether made by Kinexus or any other Third Party.
- 8.2 <u>Security</u>. Customer shall take such precautions and observe such procedures necessary to protect the security of KiNET. In doing so, Customer shall exercise at least the same level of care as exercised for its confidential and proprietary material, and in no event less than a reasonable standard of care.

- 8.3 <u>Publications</u>. Subject to Sections 8.5, Customer agrees to provide acknowledgement in any presentation or publication which reports research activities that used KiNET in whole or in part, such acknowledgment to include citation to the original source used via KiNET and an acknowledgment to Kinexus.
- 8.4 <u>Websites.</u> Subject to Sections 8.5, Customer agrees to provide acknowledgement and notice in any website which reports research activities that used KiNET or reports any data extracted or developed from KiNET acknowledging the database used and Kinexus.
- 8.5 <u>Trademark License Grant</u> Subject to the terms and conditions herein, Kinexus hereby grants Customer for the term of this Agreement a revocable, non-transferable, non-assignable, non-sub licensable, non-exclusive and royalty-fee license to use the license marks solely for and in connection with the acknowledgment and notice requirements set forth in Sections 8.3 and 8.4 above.
- 8.6 <u>Compliance.</u> Customer shall cause the appropriate designation "TM" or the registration symbol "®" to be placed adjacent to the License Marks in connection with the use thereof and to indicate such additional information as Licensor shall reasonably specify from time to time concerning the licenses rights under which Customer uses the Licensed Marks. Customer shall place the appropriate notice on all printed or electronic materials on which the Licensed Marks are trademarks and/or service marks of Kinexus.

9. TERMINATION

- 9.1 The license granted in Section 2 shall automatically be renewed at the conclusion of the access term unless terminated earlier by Kinexus or terminated by Customer as provided herein.
- 9.2 In the event that Kinexus reasonably believes in its sole discretion that Customer has breached the provisions of this Agreement, Kinexus may immediately suspend the license granted in section 2; such suspension shall be followed promptly with written notice to Customer vial email, facsimile, standard or overnight mail to the address provided herein. If Customer, within such thirty (30) day period, demonstrates to Kinexus' reasonable satisfaction that no breach existed or that such breach has been rectified, then Kinexus will reinstate the license granted in Section 2 immediately upon such determination. However, if Customer, within thirty (30) days of such written notice, fails to demonstrate in writing either that there was no breach or that such breach has been rectified to Kinexus' reasonable satisfaction, Kinexus may terminate this Agreement and all licenses granted hereunder immediately without any further notice.
- 9.3 Kinexus may terminate this Agreement with or without cause upon two (2) months written notice to Customer, or in the event of a material breach by Customer, upon thirty (30) days written notice to Customer.
- 9.4 In the event of termination by the Customer, no pro-rated fees are refundable for the remaining period of the subscription.
- 9.5 Upon termination or expiration of this Agreement, the licenses granted hereunder shall terminate immediately. Section 1, 4, 6, 7, 8, 9 and 10 shall survive termination or expiration of the Agreement.

10. GENERAL PROVISIONS

10.1 <u>Severability</u>. If any term or condition is found by a court or administrative agency to be invalid or unenforceable, the remaining terms and conditions shall remain in full force and effect and shall be enforceable to the maximum extent permitted by law.

- 10.2 <u>Governing Law; Consent to Personal Jurisdiction</u>. This Agreement shall be governed by and construed in accordance with the laws of the Province of British Columbia, without regard to the conflicts of law principles thereof. Customer hereby expressly consents to the personal jurisdiction of the state and federal courts of British Columbia for any lawsuit or action filed there against Customer by KiNET arising from or relating to this Agreement.
- 10.3 <u>Injunctive Relief</u>. A breach by the Customer of any proprietary rights of the provisions of this Agreement may cause Kinexus irreparable damage, for which the award of damages would not be adequate compensation. Consequently, Kinexus may institute an action to enjoin the breaching party from any and all acts in violation of those provisions, which remedy will be cumulative and exclusive, and Kinexus may seek the entry of any injunction enjoining any breach or threatened breach of those provisions, in addition to any other relief to which Kinexus may be entitled at law or in equity.
- 10.4 <u>Indemnity</u>. Customer shall defend, indemnify and hold Kinexus harmless from and against any and all losses, liabilities, damages, demands, suits and related costs and expenses that Kinexus may incur or suffer arising out of, resulting from or related to any breach of the Agreement by Customer or its agent, or any act or omission or failure of Customer or its agent to perform any of the representations, warranties or agreements contained herein.
- 10.5 <u>Successors and Assigns</u>. This Agreement shall be binding upon and for the benefit of Customer's successors and assigns, provided, however, that this Agreement may not be assigned by Customer without the prior written consent of Kinexus.
- 10.6 <u>Entire Agreement.</u> This Agreement constitutes the entire understanding of the parties with respect to the matters referred to herein and supersedes all prior negotiations, commitments and understandings with respect thereto, No variation or modification of the Agreement or waiver of any terms or provisions hereof shall be deemed valid unless in writing and signed by authorized representatives of both parties.

11. EXECUTION

By signing this Agreement, the Customer certifies they are an Authorized End User according to the aforementioned definition and that they accept this License Agreement in full. Kinexus' willingness to license access of KiNET to Customer is expressly conditional on acceptance of all terms in this Agreement.

IN WITNESS WHEREOF, the parties have caused their duly authorized officer to execute and deliver this Agreement as of the Effective Date.

Printed Name of Institute or Company	KINEXUS BIOINFORMATICS CORPORATION
Per:	Per: Signature of Dr. Steven Pelech
Name:	Dr. Steven Pelech
Title:	President and Chief Scientific Officer
Date signed:	Date signed:



KINEXUS

EXHIBIT A

AUTHORIZED SITE FOR SINGLE END USER

Name of institution:
Department:
Address:
Customer:
Name:
Address:
Phone:
Fax:
E-mail:
Stable IP addresses *:

* To find out your IP address, go to the following site: http://whatismyipaddress.com/

Table of contents

Table of contents	2
Application Overview	3
Homepage	4
Home	5
Logout	5
Contact us	5
FAQ	6
Help	7
Change password	7
Protein Target1	0
Protein Profile	1
Proteins Details	2
Protein Comparison1	2
Treatment14	4
Treatment Details	5
Model System 1	6
Sample Details	7
Sample Comparison	8
Kinetworks Screen 1	9
Screen Details	0
Pathways	1
GO Terms	21
Protein List	2
Order Number	3
Summary Report	4
Comparison Report	5
PhosphoNET	5

Application Overview

The KiNET application allows both paid and free subscribers easy access to the experimental data from KiNETWORKS screens. Users can not only view this data in traditional reports; they can also analyze and compare the data to discover new relationships using the large collection of proteomic data.

KiNET currently has 2 basic user types; the free (restricted) user, and the full (paid) user. The free user has access to the entire functional application, but can only see a limited set of data. This set of data is usually limited to a single organism, and possibly only control data for the various treatments. The full user can see the entire functional application as well as all of the available data. Subscriptions are generally purchased on an annual basis.

Homepage

After logging into the application the users see the KiNET homepage. The workspace is a point of entry to all main areas of the application. The Home, Logout, Contact us, FAQ and Help buttons will also appear on each page. Users can navigate to the five main areas of the Kinexus data: Protein Target, Protein Comparison, Treatment, Model System, Kinetworks Screen and Order. There are also two others buttons: one to link to the future PhosphoNET application and the other leading to the "Change password" area.

The homepage will also display the current Kinetworks statistics (number of Protein Measurements, Protein Bands, Treatments, Immunoblots, Samples and Orders).

	DEFINITIONS FAQ HELP	KINEXUS BIDINFORMATICS
Search by		
PROTEIN TARGET	Welcome to your KiNET workspace. Bob	Smith
PROTEIN COMPARISON	Search data, perform analysis, and gene	erate reports using the navigation buttons.
TREATMENT	KiNET Statistics	
MODEL SYSTEM	Number of Protein Measurements:	59972
KINETWORKS [™] SCREEN	Number of Protein Bands:	1401
ORDER NUMBER	Number of Treatments:	877
PhosphoNET	Number of Immunoblots:	2855
	Number of Samples:	2814
	Number of Orders:	400
Change Password		

Home

This button that appears on every page of the application allows the user currently logged in to go back to the entry point of the site at any time.

Logout

This button helps the users log out of KiNET and ends their session in the application. By using that button the users end up on the page shown below. If the user wishes to login in again, click the button that will return them to the login page (seen on the cover of this manual).



Contact us

This button allows the users to email Kinexus for information about KiNET. It opens the email software installed on the computer being used and set the email to be sent. Currently the email goes to <u>info@kinexus.ca</u> and has the subject "Information request or suggestion for KiNET".

FAQ

By using the FAQ button, the users bring up the 'Frequently Asked Questions' page as shown below. The input field at the left of the search button, allow them to enter any term they are looking for in the list of FAQs. The search brings back in the report below all the questions that contains the term that was searched for.

To view the answer to any question, the user should click on the question in the report. It will lead them to a new page showing the question, its answer and under them a report with all the FAQs. The return button on the page brings them back to the FAQ search page.



HOME LOGOUT DEFINITIONS FAD HELP KI	NEXUS BIDINFORMATI	
HOME LOGOUT DEFINITIONS FAD HELP KI	NEXUS BIOINFORMATI	
		165
(MIA OTIAN		
What is a Sampla?		
Answer		
A Sample is an extracted proteomic subset from a cell line or tissue to be	assayed.	
Questions		
Questions	15 questions	
Questions	15 questions	
Questions < Question <u>What is a Sample?</u>	15questions	
Cuestions < Guestion What is a Sample? What does CPM mean?	15 questions	
Questions Question What is a Sample? What is a CPM mean? How is the data normalized?	15 questions	
Cuestions	15questions	
Curestions Curestion What is a Sample? What is an Corter? How is the data normalized? What is an Order? How are Proteins chosen for a Screen?	15 questions	
Cuestions	15 questions	
Ottestions Vhat is a Sample? What does CPM mean? How is the data normalized? What is an Order? How are Proteins chosen for a Screen? What is a Band Measurement? What is a Band?	15questions	
Questions Vhat is a Samde? What is a Samde? What is an Order? How are Proteins chosen for a Screen? What is a Band Measurement? What is a Band? What is a Band? What is a Band? What is a Band?	15 questions	
Questions What is a Sample? What does CPM mean? How is the data normalized? What is an Order What is an Order How are Proteins chosen for a Screen? What is a Band? What is a Band? What is a Screen? What are DTargeted ProteinsD?	15 questions	
Cuestions vNnst is a Sample? What does CPM mean? How is the data normalized? What is an Order? How are Proteins chosen for a Screen? What is a Band Measurement? What is a Band Acoust What is a Screen? What is a Screen? What is a Screen? What is a Coll? What is a Coll?	15 questions	
< Question	15 questions	

Help

The Help button provides an access to this user documentation. When users hits this button, a new browser window opens with the .pdf file of the user documentation loaded in it. Viewing of this will require the users PC to have Acrobat Reader installed.

Change password

This is the area where a user can change his/her password. This button is only available from the user's homepage. When the users click that button, they are taken to a page where they are asked to enter their current password and their new password twice.

НОМЕ	LOGOUT	DEFINITIONS	T M FAQ	HELP	KINEXU	S BIOIN	IFO
	Current n	assword					
	Carrenty	355000					
	New pass	word					
	Confirm p	assword					
				Submit			

If they enter a wrong current password or two different new passwords or fail to fill one of the three input fields, they end up on a page where they are asked to re-enter the information.

K	
Номе	LOBOUT DEFINITIONS FAQ HELP KINEXUS BIDINFORMATICS
	You have entered a wrong current password or two different new passwords. Please repeat the operation to proceed.
	Current password
	New password
	Confirm password
	Submit

If the inputs are correct a page telling the users that their passwords have been changed will appear. From there they can go back to the homepage and continue using KiNET.



Protein Target

Here users can browse a list of all the proteins (bands) represented in the application, along with their basic annotation. This page also includes an input field to search by protein (band name) and a drop down menu to search by screen. Selecting a protein from the list will display the protein profile for that protein. Selecting Locus, MIM or Refseq in the table will open a new browser window to the appropriate web page. The different columns of the report are sortable; by clicking on the column header the users will sort its contents. This is true for most reports within KiNET.

Report column headers: Protein, Abbreviation, Phospho-Epitope, Predicted Molecular Mass (kDa), Kinetworks Screen, Locus, MIM, Refseq.



Protein Profile

This page allows the users to view all the samples that a particular protein has been measured on for a given screen.

The users can refine this list by selecting from Species, Sex, Organ, Tissue/Cell, Cell Line, Kinexus ID, Order Number, Control, Disease, Treatment, Duration, Concentration, and Primary Cells. Users can click on the Kinexus ID in the report to be taken to the sample details page.

As well, at the bottom of the page there are some basic statistics. The first row is for all measurements for that protein shown in the above report. The second row is for all measurements for that protein for this screen.

Report column headers: Kinexus ID, Control CPM, Normalized CPM(Treatment CPM), %CFC, % of Max, Species, Sex, Organ, Tissue/Cell, Primary Cells, Cell Line, Control, Disease, Treatment, Sample Details.



Proteins Details

It provides basic information on the proteins measured and has hyperlinks to Pubmed, Swissprot, Refseq, OMIM and LocusLink. The appropriate database name will not appear hyperlinked if the Protein does not have the required information.

Hame Lobadur Definitions Page Help KINEXUS BIUTNFURMATIONS Search by Protein Name: Aurora 2 (AurB, beta) protein-serine kinase PROTEIN FROFILE Gene Name: STK8 PROTEIN comparison PubMed Link: Aurora 2 (AurB, beta) protein-serine kinase PROTEIN DETAILS PubMed Link: Aurora 2 (AurB, beta) protein-serine kinase TREATMENT SwissProt Link: STK9_HUMAN MODEL SYSTEM Refseq Link: NM_003600 RINETWORKS TM SCREEN OMIM Link: 602667 Roben NUMBER Locuslink Link 6790			
Search by Protein Name: Aurora 2 (AurB, beta) protein-serine kinase PROTEIN PROFILE Gene Name: STK6 PROTEIN COMPARISON Protein Mine: STK6. PROTEIN DETAILS PubMed Link: Aurora 2 (AurB, beta) protein-serine kinase MODEL SYSTEM SwissProt Link: STK6. Refseq Link: NM. 003600 KINETWORKS ^{IN} SCREEN OMM Link: 602687 ORDER NUMBER Locuslink Link 8790		DEFINITIONS	FAQ HELP KINEXUS BIDINFORMATICS
PROTEIN TARGET Protein Name: Aurora 2 (AurB, beta) protein-serine kinase PROTEIN PROFILe Gene Name: STK6 PROTEIN COMPARISON Aurora 2 (AurB, beta) protein-serine kinase PROTEIN DETAILS PubMed Link: Aurora 2 (AurB, beta) protein-serine kinase Refseq Link: NM_003600 KINETWORKS [™] SCREEN OMIM Link: B02687 ORDER NUMBER Locuslink Link: 0790	Search by		
PROTEIN PROFILE Gene Name: STK6 PROTEIN COMPARISON Aurora 2 (Aure), beta) protein-serine kinase PROTEIN DETAILS PubMed Link: Aurora 2 (Aure), beta) protein-serine kinase TREATMENT SwissProt Link: STK6_HUMAN MODEL SYSTEM Refseq Link: NM_003800 KINETWORKS [™] SCREEN OMIM Link: 602687 ORDER NUMBER Locuslink Link: 6790	PROTEIN TARGET	Protein Name:	Aurora 2 (AurB, beta) protein-serine kinase
PROTEIN COMPARISON PROTEIN DETAILS PubMed Link: Aurora 2 (AurB, beta) protein-serine kinase TREATMENT SwissProt Link: ISTKG_HUMAN MODEL SYSTEM Refseq Link: NM_003600 KINETWORKS [™] SCREEN OMIM Link: 602687 ORDER NUMBER Loeuslink Link 6790	PROTEIN PROFILE	Gene Name:	STK6
PROTEIN DETAILS PubMed Link: Aurora 2 (AurB, beta) protein-serine kinase TREATMENT SwissProt Link: ISTKG_HUMAN MODEL SYSTEM Refseq Link: NM_003600 KINETWORKS TM SCREEN OMIM Link: 602687 ORDER NUMBER Loeuslink Link: 16790	PROTEIN COMPARISON		
TREATMENT SwissProt Link: STK6_HUMAN MODEL SYSTEM Refseg Link: NM_003600 KINETWORKS™ SCREM OMIM Link: 602687 ORDER NUMBER Locuslink Link: 6790	PROTEIN DETAILS	PubMed Link:	Aurora 2 (AurB, beta) protein-serine kinase
MODEL SYSTEM Refseq Link: NM_003600 KINETWORKS [™] SCREEN OMIM Link: 602687 ORDER NUMBER Locuslink Link: 67.90	TREATMENT	SwissProt Link:	STK6_HUMAN
KINETWORKS™ SCREEN OMIM Link: 602687 ORDER NUMBER PhosphoNET Locuslink Link 6790	MODEL SYSTEM	Refseq Link:	<u>NM_003600</u>
OMM Link: <u>602687</u> ORDER NUMBER PhosphoNET	KINETWORKS [™] SCREEN		
PhosphoNET Locuslink Link 6790	ORDER NUMBER	OMIM Link:	
	PhosphoNET	Locuslink Link	<u>6790</u>

Protein Comparison

This page allows the users to perform a pairwise comparison of protein measured on a same screen. The search brings back details of the samples where the 2 proteins appear.

On this page the users must first select a screen to compare, then the dropdown boxes for Protein #1 and Protein #2 are filled with the proteins from that screen. The users can then pick one protein in each drop-down box and compare them. They can also narrow down the results using the comboboxes on the right.

As part of the results, the users see the value of the Pearson correlation coefficient computed from the values of the %CFC for the 2 proteins on each sample. As part of the computation of the correlation coefficient a max value has been set and that value is used in the calculation whenever the %CFC is greater than that max value. It helps correct the impact of very high %CFC values on the overall calculation (this is usually the result of a very

small control value). The max value is set by the data administrator and that value appears in the input field below the correlation coefficient value.

Report column headers: Kinexus ID, Protein #1 %CFC, Protein #2 %CFC, Species, Sex, Organ, Tissue, Primary Cells, Cell Line, Control, Disease, Treatment, Sample Details, Kinetworks Screen.



Treatment

This page allows the users to search through KiNET to find what treatments have been applied to samples. The users can search by Treatment Name, Treatment Concentration and Treatment Duration. The users can then see how many samples are in the system with any given treatment.

Report Column headers: Name, Concentration, Duration, Number of Samples treated, Number of Samples available to "Free" Users.

HOME LOGO	UT DEFINITIONS FAQ HELP	KINEX	US BIO	INFORMA	TIC
Search by	Treatment Search				
PROTEIN TARGET	Treatment Name na				
PROTEIN COMPARISON	Treatment Concentration		SEAR	СН	
TREATMENT	Treatment Duration				
MODEL SYSTEM				140 Tre:	atment
	< Name	< Concentration	< Duration	< Number of Sample	< Numb
CINETWORKS™ SCREEN	1, extracellular regulated kinase-1 [Erk1, p44 MAP kinase] siF	RI -	-	1	0 4
	1. inhibitor of NE-kappa B kinase kinase alpha [IKK-alpha] -/- I	<u>-</u> ki -	-	3	0
DRDER NUMBER	1 inhibitor of NE-kanna B kinase kinase alpha [IKK-alpha] + (+		-	1	0
	1 L V294002 (PI 3-kinese inhibitor)	10.uM	30 min	2	0
hosphoNET	1 L V294003 (PL3-kinese inhibitor)	50 uM	3 br	2	0
	1 n53 dominant narrative mutant stable expression	30 GM	511	8	0
	1 ncDNA31 emity vector transfection			1	0
	1 ncDNA31+ empty vector transfection	2		1	0
	1 ncDNA3.1+ with LEDGEn75 transfection			1	0
	1. protein kinase B IPKB. Akt E40K (constitutively active) over	-	-	12	0
	1. protein kinase B (PKB, Akt) wild type	-	-	12	6
	1. protein kinase B (PRB, Akt) Wild-type	-	-	12	0
	Potent kinase c-epsilon (PKC-epsilon) over-expression	-	-	5	0
	1. Rail protein kinase stable transfection	-	- Quunalua	2	0
	1. Sodium chionae (Naci, sail)	0.0%	5 Weeks	2	0
	1. verteportin protodynamic therapy	-	- 20 min	2	0
	1. wortmannih (PI 3-kinase inhibitor) pretreatment	- 1	Ju min	0	0
	1273 SirvivA + anti-p1 + horoplast growth factor 2 [FGF2]	1 UW (FGF2)	15 mm	4	0
	2.2.2.3 directions 1 constituents (DMNO)	4C uM	2111 20 min	4	0
	2. 2,3-ametrioxy-1-napritrioquinone [Dwing]	40 UNI	ou min O lee	4	0
	 cimetry varacin (DMV) (MAP kinase phosphatase inhibitor) citta (mapping) (mapping) (citta (mapping)) 	<u>1</u> 3 UNI	∠ 111 2 daua	4	0
	2. G416 (rieomycin analogue) (antibiotic)	Zeo nM	o uays	2	0
	2. geigenen singelage innen 4. (UCV41.4.194 in a stight - 11-19	r mg/kg body weight	∠ weeks	4	0
	 nerpes simplex virus 1 [HSV1] (UV-inactivated) here a factivity 7D40001 (anidemultation the factor (EQE)) 	5 M.U.I.	ou min	1	0
	2. iressa (gentinio, 201639) (epidermai growth factor (EGF) i	COmmunities	20 nr	0	0
	2. minucycline (Dynacin, Minocin) (antibiotic)	SU mg/Kg	ZA dally, Z days	1	0
	2. SUT1274 (Met receptor-tyrosine kinase innibitor)	SUM	1 dáy	1	0
	2. wortmannin (PI 3-kinase inhibitor)	100 nM	45 min	3	U
	2. wortmannin (PI 3-kinase inhibitor) pretreatment	-	30 min	6	0
	3. wortmannin (PI 3-kinase inhibitor)	100 nM	45 min	3	0
	5-lipooxygenase inhibitor [MK886] + zVAD FMK (caspase inh	11 40 uM + 50 uM40 uM + 50 uM	15 hr	1	U
	5-Innovvnenase inhihitor IMK8861 + 7VAD EMK (casnase inh	M 411 LIM + 511 LIM	111 hr	13	111

Treatment Details

This page lists the samples in the system for the selected treatment. Report Column headers: Kinexus ID, Species, Sex, Organ, Tissue, Primary Cells, Cell Line, Disease, Treatment, Sample Details, Kinetworks Screen.

Search by PROTEIN TARGET PROTEIN COMPARISON TREATMENT Sample Information for the Treatment: TREATMENT DETAILS SIRNA (control, water) for 4 days MODEL SYSTEM			
PROTEIN TARGET PROTEIN COMPARISON TREATMENT Sample Information for the Treatment: TREATMENT DETAILS SIRNA (control, water) for 4 days MODEL SYSTEM			
PROTEIN COMPARISON TREATMENT Sample Information for the Treatment: TREATMENT DETAILS SIRNA (control, water) for 4 days MODEL SYSTEM			
TREATMENT Sample Information for the Treatment: TREATMENT DETAILS siRNA (control, water) for 4 days MODEL SYSTEM SiRNA (control, water)			
TREATMENT DETAILS SIRNA (control, water) for 4 days MODEL SYSTEM			
MODEL SYSTEM			
KINETWORKS [™] SCREEN			
ORDER NUMBER			
PhosphoNET		4	Samples
Kinexus ID < Species < Sex < Organ < Tissue	< Primary Cells	< Cell Line	< Disease
5191 human female cervix epithelium		HeLa adenocarcino	r cervical car
5194 human female cervix epithelium		HeLa adenocarcino	r cervical car
5529 human female cervix epithelium		HeLa adenocarcino	r cervical car
		HeLa adenocarcino	r cervical car

Model System

This page displays a search for model systems (samples) and some basic information on each. The users can also search for a sample by annotation elements using a series of input fields. Selecting a sample will display its details.

Report column headers: Kinexus ID, Species, Sex, Organ, Tissue, Primary Cells, Cell Line, Control, Disease, Treatment, Cell State / Fractionation, Sample Details, Kinetworks Screen.

ном	IE LOGO	סטדונ	DEFINITIONS	FAQ HELP	K I	NEXUS BIOIN	FORM	MATIC
Search by		Species			Kinexus ID			
PROTEIN TA	RGET	Sex			Order Numt	ber		
PROTEIN CO	MPARISON	Organ	bl	lood	Kinetworks	Screen		•
		Tissue			Control			-
REATMEN	т	Primary	Cells		J Disease			
ODEL SYST	EM	0.000	_		i i i i i i i i i i i i i i i i i i i			
	STM SCREEN	Cell Line				Tation		-
CINE I WORK	S. SCREEN	Treatme	ent		 Cell State 			-
ORDER NUM	BER				CEADOU			
PhosphoNET								296 Resul
< Kinexus ID	< Species	< Sex	< Organ	< Tissue	< Primary Cells	< Cell Line	< Control	< Disease
3680	human	mixed or r	rblood			MM6 monoblastic	TRUE	leukemis_
3680 3681	human human	mixed or r mixed or r	r blood r blood			MM6 monoblastic MM6 monoblastic	TRUE FALSE	leukemis_ leukemis
3680 3681 3682	human human human	mixed or i mixed or i mixed or i	r blood r blood r blood			MM6 monoblastic MM6 monoblastic MM6 monoblastic	TRUE FALSE FALSE	leukemis leukemis leukemis
3680 3681 3682 3683	human human human human	mixed or r mixed or r mixed or r mixed or r	r blood r blood r blood r blood			MM6 monoblastic MM6 monoblastic MM6 monoblastic MM6 monoblastic	TRUE FALSE FALSE FALSE	leukemia leukemia leukemia leukemia
3680 3681 3682 3683 3775	human human human human human	mixed or n mixed or n mixed or n mixed or n mixed or n	r blood r blood r blood r blood r blood	bone marrow		MM6 monoblastic MM6 monoblastic MM6 monoblastic MM6 monoblastic Reh lymphoblastic	TRUE FALSE FALSE FALSE TRUE	leukemis leukemis leukemis leukemis leukemis
3680 3681 3682 3683 3775 3776	human human human human human human	mixed or i mixed or i mixed or i mixed or i mixed or i mixed or i	r blood r blood r blood r blood r blood r blood	bone marrow bone marrow		MM6 monoblastic MM6 monoblastic MM6 monoblastic MM6 monoblastic Reh lymphoblastic Reh lymphoblastic	TRUE FALSE FALSE FALSE TRUE FALSE	leukemis leukemis leukemis leukemis leukemis leukemis
3680 3681 3682 3683 3775 3776 3808	human human human human human human human	mixed or n mixed or n mixed or n mixed or n mixed or n mixed or n mixed or n	r blood r blood r blood r blood r blood r blood	bone marrow bone marrow bone marrow		MM6 monoblastic MM6 monoblastic MM6 monoblastic Reh lymphoblastic Reh lymphoblastic Reh lymphoblastic Reh lymphoblastic	TRUE FALSE FALSE FALSE TRUE FALSE TRUE	leukemis leukemis leukemis leukemis leukemis leukemis leukemis
3680 3681 3682 3683 3775 3776 3808 3809	human human human human human human human	mixed or n mixed or n	r blood r blood r blood r blood r blood r blood r blood	bone marrow bone marrow bone marrow bone marrow		MM6 monoblastic MM6 monoblastic MM6 monoblastic MM6 monoblastic Reh lymphoblastic Reh lymphoblastic Reh lymphoblastic Reh lymphoblastic	TRUE FALSE FALSE FALSE TRUE FALSE TRUE FALSE	leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis
3680 3681 3682 3683 3775 3776 3808 3809 3978	human human human human human human human human human	mixed or n mixed or n	r blood r blood r blood r blood r blood r blood r blood r blood blood	bone marrow bone marrow bone marrow bone marrow		MM6 monoblastic MM6 monoblastic MM6 monoblastic Reh lymphoblastic Reh lymphoblastic Reh lymphoblastic Reh lymphoblastic Reh lymphoblastic Jurkat T lymphocyti	TRUE FALSE FALSE FALSE TRUE FALSE TRUE FALSE c TRUE	leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis
3680 3681 3682 3683 3775 3776 3808 3809 3978 3979	human human human human human human human human human human	mixed or n mixed or n male male	r blood r blood r blood r blood r blood r blood r blood blood blood blood	bone marrow bone marrow bone marrow bone marrow		MM6 monoblastic MM6 monoblastic MM6 monoblastic MM6 monoblastic Reh lymphoblastic Reh lymphoblastic Reh lymphoblastic Reh lymphoblastic Jurkat T lymphocyti Jurkat T lymphocyti	TRUE FALSE FALSE FALSE TRUE FALSE TRUE FALSE c TRUE c FALSE	leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis
3680 3682 3682 3775 3776 3808 3809 3978 3979 4044	human human human human human human human human human human	mixed or n mixed or n male male female	blood blood blood blood blood blood blood blood blood blood	bone marrow bone marrow bone marrow bone marrow		MM6 monoblastic MM6 monoblastic MM6 monoblastic Reh lymphoblastic Reh lymphoblastic Reh lymphoblastic Reh lymphoblastic Jurkat T lymphocyti Jurkat T lymphocyti CCRF-CEM lympho	TRUE FALSE FALSE FALSE TRUE FALSE TRUE FALSE TRUE FALSE TRUE FALSE TRUE FALSE CRUE CRUE CRUE TRUE	leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis
3680 3682 3683 3775 3776 3808 3809 3978 3979 4044 4045	human human human human human human human human human human	mixed or n mixed or n male male female female	blood blood blood blood blood blood blood blood blood blood blood	bone marrow bone marrow bone marrow bone marrow		MM6 monoblastic MM6 monoblastic MM6 monoblastic Reh lymphoblastic Reh lymphoblastic Reh lymphoblastic Reh lymphoblastic Reh lymphoblastic Jurkat T lymphocyti Jurkat T lymphocyti CCRF-CEM lymphob CCRF-CEM lymphob	TRUE FALSE FALSE FALSE TRUE FALSE	leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis
3680 3682 3683 3775 3776 3808 3809 3978 3979 4044 4045 4046	human human human human human human human human human human human	mixed or i mixed or i male female female female	blood blood blood blood blood blood blood blood blood blood blood	bone marrow bone marrow bone marrow bone marrow		MM6 monoblastic MM6 monoblastic MM6 monoblastic Reh lymphoblastic Reh lymphoblastic Reh lymphoblastic Reh lymphoblastic Reh lymphoblastic Jurkat T lymphocyti Jurkat T lymphocyti CCRF-CEM lymphot CCRF-CEM lymphot	TRUE FALSE FALSE FALSE FALSE TRUE FALSE TRUE FALSE TRUE FALSE TRUE FALSE TRUE FALSE OFALSE OFALSE	leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis
3680 3681 3682 3683 3775 3776 3809 3809 3978 3979 4044 4045 4046 4047	human human human human human human human human human human human human	mixed or r mixed or r male female female female	blood blood blood blood blood blood blood blood blood blood blood blood	bone marrow bone marrow bone marrow bone marrow		MM6 monoblastic MM6 monoblastic MM6 monoblastic Reh lymphoblastic Reh lymphoblastic Reh lymphoblastic Reh lymphoblastic Jurkat T lymphocyti Jurkat T lymphocyti CCRF-CEM lymphot CCRF-CEM lymphot CCRF-CEM lymphot	TRUE FALSE FALSE FALSE FALSE TRUE FALSE TRUE FALSE CRUE FALSE OFALSE OFALSE OFALSE OFALSE	leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis
3680 3681 3682 3765 3775 3776 3808 3809 3979 3979 4044 4045 4044 4045 4044	human human human human human human human human human human human human human human human human	mixed or r mixed or r male female female female female female	blood blood blood blood blood blood blood blood blood blood blood blood blood blood	bone marrow bone marrow bone marrow bone marrow		MM6 monoblastic MM6 monoblastic MM6 monoblastic Reh lymphoblastic Reh lymphoblastic Reh lymphoblastic Reh lymphoblastic Jurkat T lymphocyti CCRF-CEM lymphobl CCRF-CEM lymphobl CCRF-CEM lymphobl CCRF-CEM lymphobl CCRF-CEM lymphobl	TRUE FALSE FALSE TRUE FALSE TRUE FALSE TRUE FALSE TRUE FALSE TRUE FALSE C TRUE O TRUE O FALSE O FALSE O FALSE O FALSE	leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis
3680 3681 3682 3683 3775 3776 3808 3809 3979 3979 4044 4045 4044 4045 4046 4047 4048	human human human human human human human human human human human human human human human	mixed or n mixed or n female female female female female female	blood blood blood blood blood blood blood blood blood blood blood blood blood blood blood blood	bone marrow bone marrow bone marrow bone marrow		MM6 monoblastic MM6 monoblastic MM6 monoblastic Reh lymphoblastic Reh lymphoblastic Reh lymphoblastic Reh lymphoblastic Reh lymphoblastic Jurkat T lymphocyti Jurkat T lymphocyti CCRF-CEM lymphot CCRF-CEM lymphot CCRF-CEM lymphot CCRF-CEM lymphot	TRUE FALSE FALSE FALSE TRUE FALSE TRUE FALSE TRUE FALSE TRUE FALSE TRUE FALSE OFALSE OFALSE OFALSE OFALSE OFALSE OFALSE OFALSE	leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis
3880 3881 3882 3883 3775 3808 3809 3879 3978 3979 4044 4045 4046 4047 4048 4047 4048 4049 4050	human human human human human human human human human human human human human human human human human	mixed or 1 mixed or 1 female female female female female female female	blood blood blood blood blood blood blood blood blood blood blood blood blood blood blood blood blood	bone marrow bone marrow bone marrow bone marrow		MM6 monoblastic MM6 monoblastic MM6 monoblastic Reh lymphoblastic Reh lymphoblastic Reh lymphoblastic Reh lymphoblastic Jurkat T lymphocyti Jurkat T lymphocyti CCRF-CEM lymphot CCRF-CEM lymphot CCRF-CEM lymphot CCRF-CEM lymphot CCRF-CEM lymphot	TRUE FALSE FALSE FALSE TRUE FALSE TRUE FALSE TRUE FALSE TRUE FALSE TRUE FALSE OFALSE OFALSE OFALSE OFALSE OFALSE OFALSE OFALSE	leukemia leukemia leukemia leukemia leukemia leukemia leukemia leukemia leukemia leukemia leukemia leukemia leukemia leukemia leukemia
3880 3881 3882 3883 3776 3808 3979 3978 3979 4044 4045 4046 4047 4048 4047 4048 4047 4048 4049 4051	human human human human human human human human human human human human human human human human human human	mixed or n mixed or n male female female female female female female female female female female	blood blood blood blood blood blood blood blood blood blood blood blood blood blood blood blood blood blood blood blood	bone marrow bone marrow bone marrow bone marrow		MM6 monoblastic MM6 monoblastic MM6 monoblastic Reh lymphoblastic Reh lymphoblastic Reh lymphoblastic Reh lymphoblastic Jurkat T lymphocyti CCRF-CEM lymphobl CCRF-CEM lymphobl CCRF-CEM lymphobl CCRF-CEM lymphobl CCRF-CEM lymphobl CCRF-CEM lymphobl CCRF-CEM lymphobl CCRF-CEM lymphobl	TRUE FALSE FALSE FALSE FALSE TRUE FALSE TRUE FALSE TRUE FALSE OTRUE FALSE OTALSE OTALSE OTALSE OTALSE	leukemia leukemia leukemia leukemia leukemia leukemia leukemia leukemia leukemia leukemia leukemia leukemia leukemia leukemia leukemia
3880 3881 3881 3882 3775 3775 3809 3878 3878 3979 4044 4045 4045 4045 4049 4049 4049 404	human human human human human human human human human human human human human human human human human human human	mixed or 1 mixed or 1 female	blood blood blood blood blood blood blood blood blood blood blood blood blood blood blood blood blood blood blood	bone marrow bone marrow bone marrow bone marrow		MM6 monoblastic MM6 monoblastic MM6 monoblastic Reh lymphoblastic Reh lymphoblastic Reh lymphoblastic Reh lymphoblastic Jurkat T lymphocyti Jurkat T lymphocyti CCRF-CEM lymphot CCRF-CEM lymphot CCRF-CEM lymphot CCRF-CEM lymphot CCRF-CEM lymphot CCRF-CEM lymphot CCRF-CEM lymphot	TRUE FALSE FALSE FALSE TRUE FALSE TRUE FALSE TRUE FALSE TRUE FALSE TRUE FALSE OFALSE IFALSE	leukemis_ leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis
3880 3881 3882 3883 3775 3808 3809 3809 3879 3979 4044 4045 4045 4046 4047 4046 4047 4048 4049 4050 4050 4051 4053	human human	mixed or 1 mixed or 1 male female female female female female female female female female female female female female female	blood blood blood blood blood blood blood blood blood blood blood blood blood blood blood blood blood blood blood blood	bone marrow bone marrow bone marrow bone marrow		MM6 monoblastic MM6 monoblastic MM6 monoblastic Reh lymphoblastic Reh lymphoblastic Reh lymphoblastic Reh lymphoblastic Jurkat T lymphocyti Jurkat T lymphocyti CCRF-CEM lymphot CCRF-CEM lymphot CCRF-CEM lymphot CCRF-CEM lymphot CCRF-CEM lymphot CCRF-CEM lymphot CCRF-CEM lymphot CCRF-CEM lymphot	TRUE FALSE FALSE FALSE FALSE TRUE FALSE TRUE FALSE TRUE FALSE TRUE FALSE TRUE FALSE ITRUE IFALSE	leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis leukemis
3880 3681 3882 3882 3775 3808 3978 3978 3979 4044 4045 4044 4045 4047 4048 4047 4048 4047 4048 4047 4048 4047 4050 4051 4050	human human	mixed or 1 mixed or 1 female female female female female female female female female female female female female female	blood blood	bone marrow bone marrow bone marrow bone marrow		MM6 monoblastic MM6 monoblastic MM6 monoblastic Reh lymphoblastic Reh lymphoblastic Reh lymphoblastic Reh lymphoblastic Jurkat T lymphocyti Jurkat T lymphocyti CCRF-CEM lymphot CCRF-CEM lymphot CCRF-CEM lymphot CCRF-CEM lymphot CCRF-CEM lymphot CCRF-CEM lymphot CCRF-CEM lymphot CCRF-CEM lymphot CCRF-CEM lymphot	TRUE FALSE FALSE FALSE FALSE TRUE FALSE TRUE FALSE TRUE FALSE TRUE FALSE TRUE FALSE ITRUE IFALSE	leukemia leukemia leukemia leukemia leukemia leukemia leukemia leukemia leukemia leukemia leukemia leukemia leukemia leukemia leukemia leukemia non - HC
3880 3881 3682 3775 3775 3776 3808 3809 3878 3979 4044 4045 4045 4045 4045 4049 4051 4052 4052 4052 4053 4289	human human	mixed or 1 mixed or 1 female	blood blood	bone marrow bone marrow bone marrow bone marrow		MM6 monoblastic MM6 monoblastic MM6 monoblastic Reh lymphoblastic Reh lymphoblastic Reh lymphoblastic Reh lymphoblastic Jurkat T lymphocyti CCRF-CEM lymphot CCRF-CEM lymphot CCRF-CEM lymphot CCRF-CEM lymphot CCRF-CEM lymphot CCRF-CEM lymphot CCRF-CEM lymphot CCRF-CEM lymphot CCRF-CEM lymphot	TRUE FALSE FALSE FALSE FALSE TRUE FALSE TRUE FALSE TRUE FALSE TRUE FALSE O'FALSE	leukemia ± leukemia leukemia leukemia leukemia leukemia leukemia leukemia leukemia leukemia leukemia leukemia leukemia leukemia leukemia leukemia leukemia leukemia leukemia leukemia non - Hc martle c
3880 3881 3882 3883 3775 3808 3809 3809 3978 3978 3978 3978 3978 4044 4045 4045 4045 4047 4048 4049 4050 4051 4052 4053 4299 4290	human human	mixed or 1 mixed or 1 female	blood blod bl	bone marrow bone marrow bone marrow bone marrow		MM6 monoblastic MM6 monoblastic MM6 monoblastic Reh lymphoblastic Reh lymphoblastic Reh lymphoblastic Reh lymphoblastic Reh lymphoblastic Jurkat T lymphocyti Jurkat T lymphocyti CCRF-CEM lymphot CCRF-CEM lymphot Z138C B-lymphoms	TRUE FALSE FALSE FALSE FALSE TRUE FALSE TRUE FALSE TRUE FALSE TRUE FALSE TRUE FALSE OFALSE OFALSE	leukemia leukemia

Sample Details

This page displays all the detailed information about a particular Kinetworks sample as well as a report of all proteins measured from that sample. You can also filter down the results in this report by entering a CPM value and hitting the search button. Selecting a protein from the report list will display the protein profile page.

Report column headers: Full name of Protein, Phospho-Epitope, Control CPM, Normalized. CPM (Treatment CPM), DFC (Difference from Control), %CFC (Percent Change from Control), Max all (all tested species), Max (same species).

	UT DEFINITIONS FAQ	HELP	K	INEXUS E		FOR	ΜΑΤΙ	C۵
Search by	Species: human		Kinexus ID:	3681				
	Sex: mixed or not specified		Order Numb	per: 609				
PROTEIN TARGET								
	Organ: blood		Kinetworks	Screen: KPSS	3-1.3			
PROTEIN COMPARISON	Tissua							
	lissue.							
TREATMENT	Primary Cells:		Disease:	leukemia				
MODEL SYSTEM								
NODEL STOTEM	Cell Line: MM6 monoblastic							3
SAMPLE DETAILS	Control: EALSE			< Treatmen	t(s)			
SAMPLE COMPARISON	Control. Incol			tumor necr	osis factor alp	oha (TNF-a	alpha Ab] m	iousi
	Cell State: Subconfluent, Pro	liferating						
KINETWORKS ^{III} SCREEN								
ORDER NUMBER	Cell Fractionation: DetergentS	olubilizedTotalLysate		I				
PhosphoNET Norm. C	CPM values between	and	SEARCH				31 Re	esult
PhosphoNET Norm. C	CPM values between	<pre>end </pre>	SEARCH	< Norm. CPM	∢%CFC	< DFC	31 Re	esult test
Korm. Q Source of Protein Adducin alpha (ADD1) [S726]	CPM values between	And Phospho-Epitope S726	Control CPM	< Norm. CPM 7,439	< %CFC 15%	< DFC 995	31 Re < Max (all 87,536	test
Norm. Q School Schol School Schol School School School School School School School S	CPM values between	And A Phospho-Epitope S726 S693	Control CPM 6,444 3,193	< Norm. CPM 7,439 3,568	« %CFC 15% 12%	< DFC 995 375	31 Re	test
Norm. 0 Norm. 0 Venture of Protein Adducin alpha (ADD1) [S726] Adducin gamma (ADD3)[S693] cAMP response element binding	2PM values between	e Phospho-Epitope S726 S693 S133	SEARCH < Control CPM 6,444 3,193 831	< Norm. CPM 7,439 3,568 1,210		< DFC 995 375 379	31 Re	test
PhosphoNET Norm. C < Full name of Protein Adducin alpha (ADD1) IS726] Adducin gamma (ADD3) IS693 cAMP response element binding Cyclin-dependent protein-serine	PM values between	and < Phospho-Epitope \$726 \$693 \$133 Y15	SEARCH < Control CPM 6,444 3,193 831 8,618	<norm. cpm<br="">7,439 3,568 1,210 7,228</norm.>	• %CFC 15% 12% 46% -16%	< DFC 995 375 379 -1,390	31 Re	test
Adducin alpha (ADD1) [S726] Adducin alpha (ADD1) [S726] Adducin qamma (ADD1) [S893] CAMP response element bindino Cyclin-dependent protein-serine Double-stranded RNA-depende	PM values between	and Phospho-Epitope \$726 \$693 \$133 \$115 T451	SEARCH ¢ Control CPM 6,444 3,193 831 8,618 712			OFC 995 375 379 -1,390 56	31 Re < Max (all 87,536 18,944 7,470 14,993 23,906	test
Norm. C Norm. C Viana Control Contrecontrol Contrel Control Control Control Control Contr	PM values between a protein 1 [S133] e kinase 1/2 (Cdc2) [Y15] (24) nt protein-serine kinase [T451] (65) verine kinase 1 [T202/Y204]	 Phospho-Epitope S726 S693 S133 Y15 T451 T202/Y204 	SEARCH < Control CPM	Norm. CPM 7,439 3,568 1,210 7,228 768 2,148	< %CFC 15% 12% 46% -16% 8% 29%	DFC 995 375 379 -1,390 56 482	31 Re < Max (all 87,536 18,944 7,470 14,993 23,906 27,176	test
Norm. C Aducin alpha (ADD1) [S726] Adducin alpha (ADD1) [S726] Adducin agmma (ADD3) [S693] cAMP response element binding Cyclin-dependent protein-serine Double-stranded RNA-depende Extracellular regulated protein-s	PM values between	and < Phospho-Epitope S726 S683 S133 Y15 T451 T202/Y204 T185/Y187	 SEARCH Control CPM 6,444 3,193 831 8,618 712 1,666 960 	< Norm. CPM 7,439 3,568 1,210 7,228 768 2,148 1,479	\$%CFC 15% 12% 46% -16% 8% 29% 54%	DFC 995 375 379 -1,390 56 482 519	31 Re < Max (all 87,536 18,944 7,470 14,993 23,906 27,176 29,506	test
PhosphoNET Norm. C CFull name of Protein Adducin alpha (ADD1) IS7261 Adducin gamma (ADD3) IS6331 Cyclin-dependent protein-serine Double-stranded RNA-depende Extracellular regulated protein-s Citycogen synthase-serine kina:	PM values between	and From the second	SEARCH ¢ Control CPM 6,444 3,193 831 8,618 712 1,666 960 1,030	< Norm. CPM 7,439 3,568 1,210 7,228 768 2,148 1,479 825		 < DFC 995 375 379 -1,390 56 482 519 -205 	31 Re < Max (all 87,536 18,944 7,470 14,993 23,906 27,176 29,506 22,707	test
Norm. C Norm. C Norm. C Ciul name of Protein Adducin alpha (ADD1) [S726] Adducin gamma (ADD1) [S726] Adducin gamma (ADD1) [S726] Cyclin-dependent bindino Cyclin-dependent protein-serine Double-stranded RNA-dependel Extracellular regulated protein-s Extracellular regulated protein-s Extracellular synthase-serine kina: Glycoogen synthase-serine kina:	PM values between	And Fhospho-Epitope S726 S693 S133 Y15 T451 T202/Y204 T185/Y187 S21 Y279	SEARCH < Control CPM	Korm. CPM 7,439 3,568 1,210 7,228 768 2,148 1,479 825 3,974	<pre> < %CFC 15% 12% 46% -16% 8% 29% 54% -20% -23%</pre>	 < DFC 995 375 379 -1,390 56 482 519 -205 -1,209 	81 R3 < Max (all 87,536 18,944 7,470 14,993 23,906 27,176 29,506 22,707 29,844	test
Norm. C Self name of Protein Adducin alpha (ADD1) IS7261 Adducin alpha (ADD3) IS8331 cAMP response element bindinc Qvclin-dependent protein-serine Double-stranded RNA-depende Extracellular regulated protein-s Extracellular regulated protein-s Extracellular regulated protein-s Glycogen synthase-serine kina: Glycogen synthase-serine kina:	2PM values between	and < Phospho-Epitope S726 S693 S133 S133 S15 T451 T202/V204 T185/V187 S21 Y279 S9	SEARCH < Control CPM	Korm. CPM 7,439 3,568 1,210 7,228 768 2,148 1,479 825 3,974 275	<pre> * %CFC 15% 12% 46% -16% 8% 29% 54% -20% -23% 15%</pre>	 < DFC 995 375 379 -1,390 56 482 519 -205 -1,209 36 	31 R 6 Max (all 87,536 18,944 7,470 14,993 23,906 22,707 29,844 14,746	
PhosphoNET Norm. C Comparing the second	2PM values between a protein 1 [S133] e kinase 1/2 (Cdc2) [Y15] (24) nt protein-serine kinase [T451] (65) verine kinase 1 [T202/Y204] serine kinase 2 [T185/Y187] se 3 alpha [Y279] (44) se 3 alpha [Y279] (44) se 3 beta [Y216] (34)	and < Phospho-Epitope	SEARCH < Control CPM	< Norm. CPM 7,439 3,568 1,210 7,228 768 2,148 1,479 825 3,974 2,75 2,876	\$%CFC 15% 12% 46% -16% 8% 29% 54% -20% -20% -23% 15% 5%	€ DFC 995 375 379 -1,390 56 482 519 -205 -1,209 36 140	31 Re 87,536 18,944 7,470 14,993 23,906 27,176 29,506 22,707 29,844 14,746 27,896	test
Norm. C Norm. C Cull name of Protein Adducin alpha (ADD1) IS726] Adducin agamma (ADD3) IS693] Adducin gamma (ADD3) IS693] Cyclin-dependent protein-serine Double-stranded RNA-depende Extracellular regulated protein-s Glycogen synthase-serine kina: Glycogen synthase-serine kina: Jun N-terminus protein-serine kina:	PM values between	 Phospho-Epitope S726 S693 S133 Y15 T451 T202/V204 T185/V187 S21 Y279 S9 S9 Y216 T183/V185 	SEARCH ¢ Control CPM 6,444 3,193 831 8,518 712 1,666 960 1,030 5,183 239 2,736 611	< Norm. CPM 7,439 3,568 1,210 7,228 768 2,148 1,479 625 3,874 275 2,876 1,012	\$%CFC 15% 12% 46% -16% 8% 29% 54% -20% -23% 15% 5% 66%	€ DFC 995 375 379 -1,390 56 482 519 -205 -1,209 36 140 401	81 Re 87,536 18,944 7,470 14,993 23,906 27,176 29,506 22,707 29,844 14,746 27,896 44,756	test
Norm. C Norm. C Summer of Protein Adducin alpha (ADD1) IS7561 Adducin agmma (ADD3) IS8931 CAMP response element binding Cyclin-dependent protein-serine Double-stranded RNA-depende Stracellular regulated protein-s Extracellular regulated protein-s Extracellular regulated protein-s Extracellular regulated protein-s Glycogen synthase-serine kinas	PM values between	and < Phospho-Epitope	SEARCH ¢ Control CPM 6,444 3,193 831 8,618 712 1,666 960 1,030 5,183 239 2,736 611 1,281	Korm. CPM 7,439 3,568 1,210 7,228 768 2,148 1,479 825 3,974 275 2,876 1,012 1,302 1,302	*%CFC 15% 12% 46% 8% 29% 54% -20% -20% -20% 5% 5% 5% 2%	 < DFC 995 375 379 -1,390 56 482 519 -205 -1,209 36 140 401 21 	31 Re 4 Max (all 87,536 18,944 7,470 14,993 23,906 22,707 29,506 22,707 29,544 14,746 27,886 44,756 16,430	esuli test
Norm. C Norm. C SPhosphoNET Norm. C Cull name of Protein Adducin alpha (ADD1) [S726] Adducin alpha (ADD3) [S593] Adducin agama (ADD3) [S593] Adducin agama (ADD3) [S593] Cylin-dependent protein-serine binding Cyclin-dependent protein-serine Kina: Glycoagen synthase-serine kina: Mitogen & stress-activated protein-serine	PM values between	and < Phospho-Epitope	SEARCH < Control CPM	< Norm. CPM 7,439 3,568 1,210 7,228 768 2,148 1,479 825 3,974 2,75 2,876 1,012 1,012 1,002 315	«%CFC 15% 12% 45% -16% 8% 29% -20% -23% 15% 5% 56% 2% -5% -5%	 < DFC 995 375 379 -1,390 56 482 519 -205 -1,209 36 140 401 21 -17 	31 Re	
Norm. C Norm. C Characteristic sectors and sectors an	PM values between	 Phospho-Epitope S726 S693 S133 Y15 T451 T202/Y204 T185/Y187 S21 Y279 S9 Y216 T183/Y185 S217/S221 S376 S376 	SEARCH ¢ Control CPM 6,444 3,193 831 8,618 712 1,666 960 1,030 5,183 239 2,736 611 1,281 332 972	Norm. CPM 7,439 3,568 1,210 7,228 768 2,148 1,479 825 3,974 225 2,876 1,012 1,002 315 1,036	*%CFC 15% 12% 46% -15% 8% 29% -23% 54% -20% -23% 55% 5% 5% 5% 5% 7%	♦ DFC 995 375 379 -1,390 56 482 519 -205 -1,209 36 140 401 21 -17 64	31 Re	test
Norm. C Norm. C Call name of Protein Adducin alpha (ADD1) IS726] Adducin alpha (ADD1) IS726] Adducin agamma (ADD3) IS693] Colin dependent protein-serine Double-stranded RNA-depende Extracellular regulated protein-s Glycogen synthase-serine kinas Glycogen synthase-serine kinas Glycogen synthase-serine kinas Jun N-terminus protein-serine kinas Jun N-terminus protein-serine kinas MARKCERK protein-serine kinas Mitogen & stress-activated prot Mitogen-activated protein-serine	PM values between	and < Phospho-Epitope	SEARCH ¢ Control CPM 6,444 3,193 831 8,618 712 1,666 9,600 1,030 5,183 239 2,736 611 1,281 332 972 3,516	< Norm. CPM 7,439 3,568 1,210 7,228 768 2,148 1,479 625 3,974 275 2,876 1,012 1,302 315 1,036 5,224	*%CFC 15% 12% 46% 8% 29% -16% 8% 29% -20% -20% -20% -20% -20% 5% 5% 5% 5% 7% 49%	¢ DFC 995 375 379 -1,390 56 482 519 -205 -1,209 36 140 401 21 -17 64 1,708	31 Re	
Aroughon Network of Protein Adducin alpha (ADD1) IS7561 Adducin alpha (ADD1) IS7563 CAMP response element binding Cyclin-dependent protein-serine Double-stranded RNA-depende Extracellular regulated protein-s Extracellular regulated protein-s Extracellular regulated protein-s Extracellular regulated protein-s Glycogen synthase-serine kinas Mitogen Synthase-serine kinas Mitogen 8 stress-activated prote Mitogen 8 stress-activated prote Mitogen 4 stress-activated prote Mitogen 4 stress-activated prote Nettry-ID-aspariate glutamate	PM values between protein 1 [S133] a kinase 1/2 (Cdc2) [V15] (24) nt protein-serine kinase [T4511 (65) verine kinase 1 [T202/V204] se 3 abpta [S21] se 3 abpta [S21] se 3 abpta [S2] se 3	and < Phospho-Epitope	SEARCH < Control CPM	Norm. CPM 7,439 3,568 1,210 7,228 768 2,148 1,479 825 3,974 275 2,876 1,012 1,032 315 1,036 5,224 1,026	 *%CFC 15% 12% 46% -16% 8% 29% -20% -20% 5% 5% 66% 2% -5% 7% 49% -34% 	 ► DFC 995 375 379 -1,390 56 482 519 -205 -1,209 36 140 401 21 -17 64 1,708 -529 	31 Re A Max (all 87,536 18,944 7,470 14,993 23,906 27,176 29,506 22,707 29,844 14,746 22,896 44,756 16,430 3,122 11,165 14,348 19,284	
Norm. C Norm. C Comparison of Protein Adducin alpha (ADD1) [S726] Adducin alpha (ADD1) [S726] Adducin alpha (ADD1) [S726] Adducin agmma (ADD3) [S693] Cyclin-dependent protein-serine Double-stranded RNA-depende Stracellular regulated protein-s Extracellular regulated protein-s Extracellular regulated protein-s Extracellular regulated protein-s Glycogen synthase-serine kina: MAPK/ERK protein-serine kina: MAPK/ERK protein-serine kina: Mitogen & stress-activated prot Mitogen-activated protein-serine kina: prothosomal protein-serine S prot nbosomal protein-serine S	PM values between	and < Phospho-Epitope	SEARCH ¢ Control CPM 6,444 3,193 831 8,618 712 1,666 960 1,030 5,183 239 2,736 611 1,281 332 972 3,516 1,555 611	< Norm. CPM 7,439 3,568 1,210 7,228 768 2,148 1,479 825 3,974 275 2,876 1,012 1,002 315 1,036 5,224 1,026 514	«%CFC 15% 12% 46% -16% 8% 29% -20% -23% 15% 66% 5% 66% 7% 49% -34% -16%	¢ DFC 995 375 379 -1,390 56 482 519 -205 -1,209 36 140 401 21 -17 64 1,708 -529 -97	31 Re	
Norm. C Norm. C Cull name of Protein Adducin alpha (ADD1) IS7261 Adducin alpha (ADD1) IS7261 Adducin alpha (ADD1) IS7361 Adducin agmma (ADD3) IS6931 Cyclin-dependent protein-serine Double-stranded RNA-depende Extracellular regulated protein-s Glycogen synthase-serine kinas Jun N-terminus protein-serine kinas Jun N-terminus protein-serine kinas Jun N-terminus protein-serine kinas Mitogen & stress-activated prot Mitogen-activated protein-serine size 70 ribosomal protein-serine S8 70 ribosomal protein-serine S8	PM values between	and < Phospho-Epitope	SEARCH ¢ Control CPM 6,444 3,193 831 8,618 712 1,666 960 1,030 5,183 239 2,736 611 1,281 332 972 3,516 1,197	< Norm. CPM 7,439 3,568 1,210 7,228 768 2,148 1,479 625 3,974 275 2,876 1,012 1,302 315 1,036 5,224 1,026 514 1,271	*%CFC 15% 12% 46% 9% 29% 54% -20% -20% -20% -20% -20% 55% 66% 2% 55% 66% 2% -5% 66% 2% -34% -34% -34% 6%	 < DFC 995 375 379 -1,390 56 482 519 -205 -1,209 36 140 401 21 -17 64 1,708 -529 -97 74 	31 Re 4 Max (all 87,536 18,944 7,470 14,993 23,906 27,176 22,707 29,844 14,746 27,896 44,756 16,430 3,122 11,165 14,348 19,284 9,386	
Norm. C Norm. C Cull name of Protein Adducin alpha (ADD1) IS7261 Adducin alpha (ADD1) IS7261 Adducin alpha (ADD3) IS8331 cAMP response element bindinc Cyclin-dependent protein-serine Double-stranded RNA-depende Extracellular regulated protein-s Extracellular regulated protein-s Extracellular regulated protein-s Extracellular regulated protein-s Glycoogen synthase-serine kinas Mitogen & stress-activated prot Mitogen & stress-activated prot Mitogen al stress-activated prot Mitogen al protein-serine Sinas Sinbosomal protein-serine S Sinbosomal protein-serine S Sinsosmal protein-serine S Sinsosmal protein-serine S	PM values between protein 1 [S133] kinase 1/2 (Cdc2) [V151 (24) rt protein-serine kinase [T4511 (65) erine kinase 1 [T202/204] erine kinase 2 [T185/V187] se 3 abeha [S21] se 3 abeha [V279] (44) se 3 abeta [V216] (34) rase (Stress-activated protein kinase) e1/2 (MK(K1/2) [S217/S221] ein-serine kinase 1 [S376] (66) ein-serine kinase 1 [S376] (74) ein-serine kinase 2 [T412] kinase 2 [T412] kitase 2 [T412] kitase 2 [T412] kitase 1 [S43]	and < Phospho-Epitope	SEARCH c Control CPM 6,444 3,193 831 8,618 712 1,666 960 1,030 5,163 239 2,736 611 1,281 332 972 3,516 1,555 611 1,197 1,084	Norm. CPM 7,439 3,568 1,210 7,228 768 2,148 1,479 825 3,974 275 2,876 1,012 1,012 1,030 315 1,036 5,224 1,026 514 1,026 514 1,271 852	 *%CFC 15% 12% 46% -16% 8% 29% -20% 5% 66% 2% -5% 7% 49% -34% -16% 6% 6% -21% 	 < DFC 995 375 379 -1,390 56 482 519 -205 -1,209 36 140 401 21 -17 64 1,708 -529 -97 74 -232 	31 Re * Max (all 87,536 18,944 7,470 14,993 23,906 27,176 29,506 22,707 29,506 22,707 29,506 22,707 29,506 22,707 29,506 3,122 11,165 16,430 3,122 11,165 14,348 19,284 19,285	esult
Norm. C Norm. C SPhosphoNET Norm. C Cull name of Protein Adducin alpha (ADD1) [S726] Adducin alpha (ADD1) [S726] Adducin alpha (ADD3) [S633] Cyolin-dependent protein-serine Double-stranded RNA-depende Extracellular regulated protein-s Extracellular regulated protein-serine kinas Glycogen synthase-serine kinas Glycogen synthase-serine kinas Glycogen synthase-serine kinas Mitogen & stress-activated prot Mitogen & stress & Bipta (A Protein-serine kinas S Protein-serine kinase B alpha (A)	PM values between	and < Phospho-Epitope	SEARCH ¢ Control CPM 6,444 3,193 831 8,618 712 1,666 960 1,030 5,183 239 2,736 611 1,281 332 972 3,516 1,555 611 1,197 1,084 278	< Norm. CPM 7,439 3,568 1,210 7,228 768 2,148 1,479 825 3,974 2,75 2,876 1,012 1,036 5,224 1,026 514 1,271 852 267	«%CFC 15% 12% 46% 46% 9% 29% -20% -20% -23% 15% 5% 66% 2% 7% 49% -16% 6% -2% -34% -16% 6% -2% -4%	 < DFC 995 375 379 -1,390 56 482 519 -205 -1,209 36 140 401 21 -17 64 1,708 -529 -97 74 -232 -11 	31 Re	

Sample Comparison

This page allows the users to view information about the sample that was selected and make quantitative comparisons to other samples from the same screen within the same order or across all orders. The users can then select a sample from one of two lists; samples from the same order as the sample selected (from the same screen), or from a list of samples from all orders (from the same screen). The sample chosen to compare will populate the report table with its CPM and other comparative values. Selecting a protein from the list will display its protein profile.

Report column headers: Full Name of Protein, Phospho-Epitope, Max (all tested species), Sample No.1Control Norm. cpm, Sample No.1 Selected Norm. cpm, %CFC for Sample #1, % of Max for Sample #1 Selected, Sample No.2 Selected Norm. cpm, %CFC for Sample No.2, % of Max for Sample No.2 Selected.

HOME		INS FAQ	HELP	KINEXUS	BIOINFORMATIC			
Search by	Kinexus ID:	2261	Sampl	e No.2 to Compare Kin	exus ID: 2262			
PROTEIN TARGET	Organ: eye		Fru	m same order Or	jan: eye			
	Tissue: come	a	2262	Tis	sue: comea			
PROTEIN COMPARISON	hasue. come		Fro	m All Orders	der No.: 346			
TREATMENT	Cell:			Ce				
MODEL SYSTEM	Treatment:			SEARCH OT				
SAMPLE DETAILS				Tre	atment:			
CANDLE CONDADTON	Order No.: 3	46						
KINETWORKS TM SCREEN	Kinetworks Screen: K	PSS-1.1		Kin Sc	etworks reen: KPSS-1.1			
ORDER NUMBER	Control: T	RUE		Co	ntrol: FALSE			
PhosphoNET					43 Result			
< Full name of Protein		< Phospho-Epitope	< Max (all tested species)	< Sample No.1 Control Norm. cpm	< Sample No.1 Treatment Norm.cpm <			
Adducin alpha (ADD1) [S726]		S726	25,679	2,069	2,069			
Adducin gamma (ADD3) [S693	1	S693	9,899	904	904			
B23 (Nucleophosmin) [S4]		S4	0	0				
CAMP response element bindin	g protein 1 [S133]	S133	21,910	1,759	1,759			
Cyclin-dependent protein-serin	e kinase 1/2 (Cdc2)	Y15	15,344	0				
Double-stranded RNA-depende	ent protein-serine kin	1451	29,968	4,888	4,888			
let a second sec	serine kinase 1 [T20]	1202/Y204	32,213	1,527	1,52/			
Extracellular regulated protein-	and a binner of the o		28,013					
Extracellular regulated protein- Extracellular regulated protein-	serine kinase 2 (T18)	1185/Y18/	7 707	117	3,036			
Extracellular regulated protein- Extracellular regulated protein- Glycogen synthase-serine kins Glycogen synthase sering kins	serine kinase 2 [T18: ase 3 alpha [S21]	S21	7,727	117	1087			
Extracellular regulated protein- Extracellular regulated protein- Glycogen synthase-serine king Glycogen synthase-serine king Glycogen synthase-serine king	serine kinase 2 [T18: ase 3 alpha [S21] ase 3 alpha [Y279] (4 ase 3 alpha [Y279] (4	S21 Y279 Y279	7,727 27,608	117 1,987	3,036 117 1,987			
Extracellular regulated protein- Extracellular regulated protein- Glycogen synthase-serine kina Glycogen synthase-serine kina Glycogen synthase-serine kina	<u>serine kinase 2 [T18: ise 3 alpha [S21] ise 3 alpha [Y279] (4 ise 3 alpha [Y279] (4 ise 3 beta [S9]</u>	S21 Y279 Y279 S9	7,727 27,608 0 8,497	5,000 117 1,987 0	3,036 117 1,987			
Extracellular regulated protein- Extracellular regulated protein- Glycogen synthase-serine kins Glycogen synthase-serine kins Glycogen synthase-serine kins Glycogen synthase-serine kins	serine kinase 2 [T18: ase 3 alpha [S21] ase 3 alpha [Y279] (4 ase 3 alpha [Y279] (4 ase 3 beta [S9] ase 3 beta [Y216] (34	S21 Y279 Y279 S9 Y216	7,727 27,608 0 8,497 0	117 1,987 0 0	3,036 117 1,987			
Extracellular regulated protein- Extracellular regulated protein- Glycogen synthase-serine kins Glycogen synthase-serine kins Glycogen synthase-serine kins Glycogen synthase-serine kins Glycogen synthase-serine kins	serine kinase 2 [T18; ase 3 alpha [S21] ase 3 alpha [Y279] (4 ase 3 alpha [Y279] (4 ase 3 beta [S9] ase 3 beta [Y216] (34 ase 3 beta [Y216] (35	1185/Y187 S21 Y279 Y279 S9 Y216 Y216	7,727 27,608 0 8,497 0 34,123	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	4,901			
Extracellular regulated protein- Extracellular regulated protein- Glycogen synthase-serine kins Glycogen synthase-serine kins Glycogen synthase-serine kins Glycogen synthase-serine kins Glycogen synthase-serine kins Glycogen synthase-serine kins Glycogen synthase-serine kins	serine kinase 2 [T18: ase 3 alpha [S21] ase 3 alpha [Y279] (4 ase 3 alpha [Y279] (4 ase 3 beta [S9] ase 3 beta [Y216] (34 ase 3 beta [Y216] (34 ase 3 beta [Y216] (34 ase 3 beta [Y216] (34 ase 3 beta [Y216] (34	1185/Y187 S21 Y279 S9 Y216 Y216 Y216 T183/Y185	7,727 27,608 0 8,497 0 34,123 12,725	0 0 0 0 0 0 0 0 0 0 0 0 0 0	4,901 268			
Extracellular regulated protein- Extracellular regulated protein- Extracellular regulated protein- Glycogen synthase-serine kins Glycogen synthase-serine kins Glycogen synthase-serine kins Glycogen synthase-serine kins Jun N-terminus protein-serine I Jun N-terminus protein-serine I	serine kinase 2 [T18: ase 3 alpha [S21] ase 3 alpha [Y279] (/ ase 3 alpha [Y279] (/ ase 3 beta [S9] ase 3 beta [Y216] (3: ainase (Stress-active kinase (Stress-active	1185/Y187 S21 Y279 S9 Y216 Y216 Y216 T183/Y185 T183/Y185	7,727 27,608 0 8,497 0 34,123 12,725 5,902	5050 117 1,967 0 0 0 4,901 268 288	4,901 268 288			
Extracellular regulated protein- Extracellular regulated protein- Glycogen synthase-serine kins Glycogen synthase-serine kins Glycogen synthase-serine kins Glycogen synthase-serine kins Glycogen synthase-serine kins Jun N-terminus protein-serine I Jun N-terminus protein-serine I Jun N-terminus protein-serine I	serine kinase 2 [T18: ssc 3 alpha [S21] use 3 alpha [Y279] (4 ssc 3 alpha [Y279] (4 ssc 3 alpha [Y216] (3: ssc 3 beta [Y216] (3: ssc 3 beta [Y216] (3: kinase (Stress-active (inase (Stress-active (39)	1185/Y187 S21 Y279 Y279 Y279 Y216 Y216 T183/Y185 T183/Y185 S73	7,727 27,608 0 8,497 0 34,123 12,725 5,902 10,328	5030 117 1,987 0 0 4,901 268 288 652	4,901 268 288 652			
Extracellular regulated protein- Extracellular regulated protein- Glycogen synthase-serine kins Glycogen synthase-serine kins Glycogen synthase-serine kins Glycogen synthase-serine kins Glycogen synthase-serine kins Glycogen synthase-serine kins Jun N-terminus protein-serine I Jun N-terminus protein-serine I Jun-o trascription factor (S73) MAP kinase kinase 3/8 (MKK3)	serine kinase 2 [T18: ses 3 alpha [S21] ses 3 alpha [Y279] (4 ses 3 alpha [Y279] (4 ses 3 beta [Y216] (3 ses 3 beta [Y216] (3 sinase (Stress-active sinase (Stress-active (39), 6) [S189/S207]	1159/16/ S21 Y279 Y279 S9 Y216 Y216 T183/Y185 S73 S189/S207	7,727 27,608 0 8,497 0 34,123 12,725 5,902 10,328 7,782	5050 117 1,987 0 0 4,901 268 288 652 125	4,901 268 268 262 125			
Extracellular regulated protein- Extracellular regulated protein- Glycogen synthase-serine kins Glycogen synthase-serine kins Glycogen synthase-serine kins Glycogen synthase-serine kins Glycogen synthase-serine kins Jun N-terminus protein-serine I Jun N-terminus protein-serine I Jun- trascription factor [S73] MAP kinase kinase 36 (MKK3)	serine kinase 2 [T18: sse 3 alpha [S21] sse 3 alpha [Y279] (4 sse 3 abeta [S9] sse 3 beta [Y216] (3 sse 3 beta [Y216] (3 inase (Stress-active dinase (Stress-active dinase (Stress-active (39) b) [S189/S207] s207]	1155/Y187 S21 Y279 Y279 S9 Y216 T183/Y185 T183/Y185 S73 S189/S207 S207	7,727 27,508 0 8,497 0 34,123 12,725 5,902 10,328 7,782 1,532	5000 117 1,987 0 0 0 4,901 268 288 652 125 261	3,036 117 1,987 4,901 268 288 652 125 261			
Extracellular regulated protein- Extracellular regulated protein- Extracellular regulated protein- Glycogen synthase-serine kins Glycogen synthase-serine kins Glycogen synthase-serine kins Jun N-terminus protein-serine I Jun N-terminus protein-serine I Jun -trascription factor [S73] MAP kinase kinase 3/8 (MKK3) MAP kinase kinase 6 (MKK6)]	serine kinase 2 [T18: sse 3 alpha [Y279] (4 sse 3 alpha [Y279] (4 sse 3 alpha [Y279] (4 sse 3 beta [S9] sse 3 beta [Y216] (3; sse 3 beta [Y216] (3; sse 3 beta [Y216] (3; sinase (Stress-active (inase (Stress-active (39) b) [S189/S207] se 1/2 (MKK1/2) [S21]	1185/y187 521 Y279 S9 Y216 Y216 Y216 T183/y185 S73 S189/S207 S207 S217/S221	7,727 27,508 0 8,497 0 34,123 12,725 5,902 10,328 7,782 1,532 35,510	5050 117 1,967 0 0 4,901 268 288 652 288 652 285 261 266	4,901 4,901 268 252 125 261 266			
Extracellular regulated protein- Extracellular regulated protein- Glycogen synthase-serine kins Glycogen synthase-serine kins Glycogen synthase-serine kins Glycogen synthase-serine kins Glycogen synthase-serine kins Jun N-terminus protein-serine I Jun N-terminus protein-serine I Jun N-terminus protein-serine I Jun N-terminus protein-serine I MAP kinase kinase 3/6 (MKK3) MAP kinase kinase 3/6 (MKK3) MAP kinase kinase 3/6 (MKK3)	serine kinase 2 [118: se 3 alpha [521] se 3 alpha [17279] (4 se 3 alpha [17279] (4 se 3 alpha [17279] (4 se 3 beta [17216] (3; se 3 beta [17216] (3; dinase (Stress-active dinase (Stress-active dina	1185/y187 521 Y279 59 Y276 Y216 Y216 Y216 T183/y185 S73 S189/S207 S207 S207 S217/S221 S376	7,727 27,608 0 8,497 0 34,123 12,725 5,902 10,328 7,782 1,532 35,310 3,188	5050 117 1,987 0 0 4,901 268 652 125 261 266 0	3,036 117 1,987 4,901 268 288 652 125 261 266			
Extracellular regulated protein- Extracellular regulated protein- Glycogen synthase-serine kins Glycogen synthase-serine kins Glycogen synthase-serine kins Glycogen synthase-serine kins Glycogen synthase-serine kins Glycogen synthase-serine kins Jun N-terminus protein-serine I Jun N-terminus protein-serine I Jun- trascription factor [573] MAP kinase kinase 3/6 (MKK3) MAP kinase kinase 6 (MKK6) [5 MAPK/ERK protein-serine kinas Mtogen & stress-activated pro Mtogen & stress-activated pro	serine kinase 2 [T18: se 3 aloha [S21] se 3 aloha [S21] se 3 aloha [Y279] (4 se 3 aloha [Y279] (4 se 3 beta [Y216] (3; sia 3 beta [Y216] (3; sinase (Stress-active (39) 5) [S189/S207] 5207] se 1/2 (MKK1/2) [S21 tein-serine kinase 1	1159/187 S21 Y279 Y279 S9 Y216 Y216 Y216 Y216 Y216 S73 S189/S207 S207 S207 S217/S221 S376 S376	7,727 27,608 0 8,497 0 34,123 12,725 5,902 10,328 7,782 1,532 35,310 3,188 4,464	5050 117 1,987 0 0 4,901 268 652 125 261 266 0 190	3,036 117 1,987 4,901 268 288 652 125 261 266 266 190			

Kinetworks Screen

The Kinetworks Screen page displays a list of all screens along with their type, description, number of Proteins generally measured on that screen and number of Samples in the application that have used that Screen. Users can also search screens by name and/or type. Screens in the list are hyperlinked and selecting a screen will open the Screen Details form.

Report column headers: Screen Name, Screen Type, Description, Proteins and Samples.

HOME LOGOU	DEFINITIONS	FAQ HELP	KINEXUS BI		DRMATIC
Search by					
PROTEIN TARGET	Screen Name				
PROTEIN COMPARISON	Screen Type		SEARCH		
TREATMENT					25. Deculto
MODEL SYSTEM	- Cavaan blama	- Cavaan Tuna	Description	Dustains	20 Results
	< Screen Name	< Screen Type	< Description	< Proteins	< Samples
KINETWORKS [™] SCREEN	KAPS-1.0	Non-Phosphospecific	Kinetworks Apoptosis Screen	31	113
	KCCP-1.0	Non-Phosphospecific	Kinetworks Cell Cycle Screen	31	86
ORDER NUMBER	KCPS-1.0	Phospho/hon-phosphospecific	Kinetworks Custom Screen	325	316
	KHSP-1.0	Non-Phosphospecific	Kinetworks Stress/Heat Shock Protein Screen	27	33
PhosphoNET	KPKS-1.0	Non-Phosphospecific	Kinetworks Protein Kinase Screen	82	0
	KPRS-1.2	Non-Phosphospecific	Kinetworks Protein Kinase Screen	104	340
	KPPS-1.1	Non-Phosphospecific	Kinetworks Phosphatase Screen	30	35
	KPPS-1.2	Non-Phosphospecific Discontractic	Kinetworks Phosphatase Screen	31	40
	KPSS-1.1	Phosphospecific	Kinetworks PriosphoSite Screen	30	0
	MP33-1.2	Phosphospecific	Kinetworks PhosphoSite Screen	33	290
	KPSS-1.0	Phosphospecific	Kinetworks PhosphoSite Screen	41	0
	KPSS.11.0	Phoenbosnecific	Kinetworks PhosphoSite Screen	31	0
	KPSS-12.0	Phosphospecific	Kinetworks PhosphoSite Screen	28	0
	KPSS-2.0	Phosphospecific	Kinetworks PhosphoSite Screen	42	115
	KPSS-2.1	Phosphospecific	Kinetworks PhosphoSite Screen	40	220
	KPSS-3.0	Phosphospecific	Kinetworks PhosphoSite Screen	42	64
	KPSS-3.1	Phosphospecific	Kinetworks PhosphoSite Screen	41	82
	KPSS-4.0	Phosphospecific	Kinetworks PhosphoSite Screen	46	166
	KPSS-4.1	Phosphospecific	Kinetworks PhosphoSite Screen	43	277
	KPSS-5.0	Phosphospecific	Kinetworks PhosphoSite Screen	35	194
	KPSS-6.0	Phosphospecific	Kinetworks PhosphoSite Screen	35	57
	KPSS-7.0	Phosphospecific	Kinetworks PhosphoSite Screen	41	0
	KPSS-8.0	Phosphospecific	Kinetworks PhosphoSite Screen	61	0
	Terresco Construction			10000	

Screen Details

This page displays a list of all the samples that have been run on this screen. This is the default page once a screen is selected. Selecting a sample will display the appropriate Sample Details page. The number of results can be narrowed down using the available choices in the drop-down boxes.

Report column headers: Kinexus ID, Species, Sex, Organ, Tissue, Primary Cells, Cell Line, Control, Disease, Treatment, Sample Details.

			r M								
HOME		EFINITIONS	FAQ			KINEXU	IS BIDINFOR	MATIC			
Search by						Species					
		Screen Name:	KCC	CP-1.0							
PROTEIN TARGET		Scroop Timo:	Non	Dhoenhoe	nocific	Organ					
		Screen type. Nore-nosphospecific					Tissue				
PROTEIN COMPARIS	SON	Description:									
TREATMENT		Kinetworks Ce	di Cycle S	creen		Sex					
IREATMENT						Control					
MODEL SYSTEM											
			SEAL	RCH		Disease					
KINETWORKS™ SCR	EEN					Primary Ce	ells				
SCREEN DETAILS						Cell Line					
PATHWAYS		Т	reatment								
GO TERMS											
PROTEIN LIST			-	_	_			86 Resu			
	< Kinexus ID	< Species	< Sex	< Organ	< Tissue	< Primary Cells	« Cell Line	< Control			
JKDEK NUMBER	3744	mouse	mixed or r		embryonic inner cell m		ES-J1 embryonic stem	TRUE			
PhoenhoNET	3745	mouse	mixed or I		embryonic inner cell m		ES-J1 embryonic stem	FALSE			
nosphorter	2200	humon	mixed or i	colon	empryonic inner cell m		ES-31 empryonic stem	TRUE			
	2002	human	mixed or i	colon	opitholium			FALSE			
	2003	human	mixed or i	colon	epitrielium			FALSE			
	3034	numan	mixed of 1	COIOT	epintelium			TALSE			
	4054	human	INVERIOUS					TRUE			
	4054	human	mixed or i					FALSE			
	4054 4055 4058	human human human	mixed or r mixed or r					FALSE			
	4054 4055 4058 4059	human human human	mixed or i mixed or i mixed or i mixed or i					FALSE FALSE FALSE			
	4054 4055 4058 4059 4428	human human human human mouse	mixed or r mixed or r mixed or r mixed or r	hrain	cerebellum			FALSE FALSE FALSE FALSE			
	4054 4055 4058 4059 4428 4429	human human human human mouse mouse	mixed or i mixed or i mixed or i mixed or i female female	brain	cerebellum			FALSE FALSE FALSE FALSE FALSE FALSE			
	4054 4055 4055 4058 4059 4428 4429 4430	human human human human mouse mouse mouse	mixed or i mixed or i mixed or i mixed or i female female	brain brain brain	cerebellum cerebellum cerebellum			FALSE FALSE FALSE FALSE FALSE FALSE TRUE			
	4054 4055 4055 4059 4428 4429 4429 4430 4431	human human human human mouse mouse mouse mouse	mixed or n mixed or n mixed or n mixed or n female female female female	brain brain brain brain	cerebellum cerebellum cerebellum cerebellum			TRUE FALSE FALSE FALSE FALSE FALSE TRUE FALSE			
	4054 4055 4058 4059 4428 4429 4429 4430 4431 4432	human human human human mouse mouse mouse mouse mouse	mixed or n mixed or n mixed or n mixed or n female female female female male	brain brain brain brain brain	cerebellum cerebellum cerebellum cerebellum cerebellum			TRUE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE			
	4054 4055 4058 4059 4428 4429 4429 4430 4431 4432 4439	human human human human mouse mouse mouse mouse mouse human	mixed or n mixed or n mixed or n female female female female male male	brain brain brain brain brain colon	cerebellum cerebellum cerebellum cerebellum cerebellum exithelium		DLD1 adenocarcinoma	TRUE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE TRUE			
	4054 4055 4058 4059 4428 4429 4430 4431 4432 4439 4440	human human human mouse mouse mouse mouse mouse human human	mixed or r mixed or r mixed or r mixed or r female female female female male male male	brain brain brain brain brain colon colon	cerebellum cerebellum cerebellum cerebellum cerebellum epithelium epithelium		DLD1 adenocarcinoma DLD1 adenocarcinoma	TRUE FALSE FALSE FALSE FALSE FALSE TRUE FALSE TRUE FALSE TRUE FALSE			
	4054 4055 4058 4059 4428 4429 4430 4431 4432 4432 4439 4440 4441	human human human human mouse mouse mouse mouse human human human	mixed or r mixed or r mixed or r mixed or r female female female female male male male male	brain brain brain brain colon colon colon	Cerebellum Cerebellum Cerebellum Cerebellum Cerebellum epithelium epithelium epithelium		DLD1 adenocarcinoma DLD1 adenocarcinoma DLD1 adenocarcinoma	TRUE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE			
	4054 4055 4058 4059 4428 4429 4430 4430 4431 4432 4439 4440 4440 4441	human human human human mouse mouse mouse mouse human human human	mixed or r mixed or r mixed or r mixed or r female female female female male male male male male	brain brain brain brain brain colon colon colon	cerebellum cerebellum cerebellum cerebellum cerebellum epithelium epithelium epithelium epithelium		DLD1 adenocarcinoma DLD1 adenocarcinoma DLD1 adenocarcinoma DLD1 adenocarcinoma	TRUE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE			
	4054 4055 4058 4428 4429 4430 4431 4431 4432 4432 4432 4440 4441 4442 4444	human human human mouse mouse mouse mouse mouse human human human human	mixed or i mixed or i mixed or i mixed or i female female female female female male male male male male male male	brain brain brain brain brain colon colon colon colon	cerebellum cerebellum cerebellum cerebellum epthelum epthelum epthelum epthelum epthelum		DLD1 adenocarcinoma DLD1 adenocarcinoma DLD1 adenocarcinoma DLD1 adenocarcinoma DLD1 adenocarcinoma	TRUE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE			
	4054 4055 4055 4428 4429 4429 4430 4430 4431 4432 4432 4432 4441 4441 4441 4442 4444	human human human mouse mouse mouse mouse human human human human human	mixed or i mixed or i mixed or i mixed or i mixed or i female female female female male male male male male male male	brain brain brain brain colon colon colon colon colon colon	cerebellum cerebellum cerebellum cerebellum cerebellum epithelium epithelium epithelium epithelium epithelium epithelium		DLD1 adenocarcinoma DLD1 adenocarcinoma DLD1 adenocarcinoma DLD1 adenocarcinoma DLD1 adenocarcinoma DLD1 adenocarcinoma	TRUE FALSE			
	4054 4055 4055 4059 4428 4429 4430 4431 4432 4432 4433 4440 4444 4441 4442 4443 4444 4445	human human human human mouse mouse mouse mouse human human human human human human human	mixed or i mixed or i mixed or i mixed or i mixed or i female female female male male male male male male male	brain brain brain brain colon colon colon colon colon colon colon	cerebeilum cerebeilum cerebeilum cerebeilum cerebeilum epitheilum epitheilum epitheilum epitheilum epitheilum epitheilum epitheilum		DLD1 adenocarcinoma DLD1 adenocarcinoma DLD1 adenocarcinoma DLD1 adenocarcinoma DLD1 adenocarcinoma DLD1 adenocarcinoma DLD1 adenocarcinoma	TRUE FALSE FALSE FALSE FALSE FALSE TRUE FALSE TRUE FALSE FALSE			

Pathways

The Pathways page displays 2 lists: metabolic and signalling pathways. Each is a list of the pathways that have proteins detected on the screen in context.

By clicking on a pathway the users will open a new window that will display the appropriate BioCarta or KEGG page.

Report column header: Pathway name.



GO Terms

This page would allow the users to select a Gene Ontology category (biological process, cellular component, molecular function) which creates a list of GO terms that are associated with proteins from the screen in context. This page is still under construction and will be available in a future version of KiNET.

Protein List

The Protein list is a report of all proteins involved on the screen in context. Selecting a protein from the list will display its protein profile.

Report column headers: Full Name, Abbreviation, Phospho-Epitope, Predicted Molecular Mass (kDa), Locus, MIM, Refseq, Measurements.

By clicking respectively on Locus, MIM and Refseq for any protein, the users can see in a new window the information for that protein from respectively Entrez Gene, OMIM and Entrez Protein.

Search by		
PROTEIN TARGET	Screen: KCCP-1.0	31 Proteins
PROTEIN COMPARISON	< Full Name	< Abbreviation
	14-3-3 protein zeta (cross-reacts with other isoforms) (22)	14-3-3?/?/?, 14-3-
REATMENT	14-3-3 protein zeta (cross-reacts with other isoforms) (24)	14-3-3?/?/?, 14-3-
	CDK5 regulatory subunit 1, p35	p35, p25
ODEL SYSTEM	Cell division cycle 25B phosphatase	Cdc25B
	Cell division cycle 25C phosphatase	Cdc25C
INETWORKS [™] SCREEN	Cell division cycle 34 (ubiquitin-conjugating ligase)	Cdc34
	Checkpoint protein-serine kinase 1	Chk1
SCREEN DETAILS	Checkpoint protein-serine kinase 2	Chk2
DATHWAYS	Cyclin A1	Cyclin A
	Cyclin B1	Cyclin B1
GO TERMS	Cyclin D1 (PRAD1)	Cyclin D1
DROTETN LITET	Cyclin E1	Cyclin E
PROTEIN LIST	Cyclin G1	Cyclin G1
RDER NUMBER	Cyclin-dependent kinase inhibitor 1 (MDA6)	p21
	Cyclin-dependent protein-serine kinase 1 (Cdc2)	Cdk1 [T14/Y15], Cl
PhosphoNET	Cyclin-dependent protein-serine kinase 2	CDK2
nosphorei	Cyclin-dependent protein-serine kinase 4	CDK4
	Cyclin-dependent protein-serine kinase 5	CDK5
	Cyclin-dependent protein-serine kinase 6	CDK6
	Cyclin-dependent protein-serine kinase 7	CDK7
	Cyclin-dependent protein-serine kinase 9	CDK9
	Cyclin-dependent kinase associated phosphatase (CDK inhibitor 3, CIP2)	KAP, KAP (C-18)
	DNA-activated protein-serine kinase	DNA-PK, DNAPK
	NIMA (never-in-mitosis)-related protein-serine kinase 2	Nek2
	p27 cyclin-dependent kinase inhibitor 1B	p27
	Polo-like protein-serine kinase 1	Plk-1, Plk1
	Proliferating cell nuclear antigen	PCNA
	Retinoblastoma-associated protein 1	Rb, Rb [T821], Rb
	Iruncated form of p35, the CDK5 regulatory subunit 1	p35, p25
	Tumor suppressor protein p53 (antigenNY-CO-13)	p53 [S392], p53
	Vee1 protein-tyrosine kinase	Wee1

Order Number

This page allows the users to select an order by its number and to navigate through its details. Orders are samples that have been grouped together usually because they are biologically relevant to each other. Also listed are the number of samples and normalization groups each order has. The users may also search by order number. Selecting an order will display the summary report for that order.

Report column headers: Order, No of Samples, Norm. Groups, No of Control Samples, Screens.

Search by	Order Search				
ROTEIN TARGET	Order Number	7	SEARCH		
ROTEIN COMPARISON	F				100 Result
	< Order	< No. of Samples	< Norm. Groups	< No. Of Control Samples	< Screens
REATMENT	700	4	2	2	KCPS-1.0, KPSS-1.3
	701	3	1	1	KPSS-2.0
ODEL SYSTEM	702	4	1	1	KPSS-5.0
	703	2	2	1	KPKS-1.2
INETWORKS [™] SCREEN	704	3	0	1	
	705	8	2	5	KPSS-5.0, KPSS-4.0
ORDER NUMBER	706	2	1	1	KPSS-4.0
	707	8	2	3	KPSS-3.0
hosphoNET	708	9	1	3	KAPS-1.0
	709	4	1	1	KPSS-5.0
	710	6	1	1	KCPS-1.0
	711	21	4	3	KPKS-1.2, KPPS-1.1, KPSS-1.3
	712	6	1	1	KPSS-5.0
	713	4	2	2	KPPS-1.1, KPSS-2.0
	714	8	1	2	KPSS-4.0
	715	3	2	1	KPKS-1.2
	716	2	1	1	KPSS-4.0
	717	4	1	2	KPSS-1.3
	718	4	1	1	KPSS-4.0
	719	2	1	2	KPSS-2.0
	720	2	1	1	KPSS-3.0
	721	3	1	1	KPKS-1.2
	722	6	3	3	KPSS-5.0, KPSS-2.0, KPSS-4 (
	723	2	1	1	KPSS-1.3
	724	2	1	1	KPSS-3.0
	725	5	1	1	KCCP-1.0
	726	6	2	2	KPSS-2.0, KAPS-1.0
	727	18	2	2	KCCP-1.0
	728	6	2	2	KPSS-1.3
	729	4	1	1	KAPS-1.0
	730	3	2	1	KPKS-1 2
	731	5	2	1	KPKS-1.2
	732	5	2	2	KCPS-1.0
	733	10	-	1	KDSS 1.3
	1100	10			10-00-1.0

Summary Report

The summary report is a qualitative list of gel type, screen, sample, and treatment information for a given order. Selecting an entry from the list will display its sample details. Please note that free users may often see no results in this report as there is no information visible to them for that Order. *Report column headers: Kinexus ID, Species, Sex, Organ, Tissue, Primary Cells, Cell Line, Control, Disease, Treatment, Sample Details, Screen, Normalization Group.*

PROTEINTARGET							
							28 Resu
PROTEIN COMPARISON	< Kinexus ID	< Species	< Sex	< Organ	< Tissue	< Primary Cells	< Cell Line
TREATMENT	4351	rat	male	epididymis	initial segment		
	4352	rat	male	epididymis	initial segment		
MODEL SYSTEM	<u>4352</u>	rat	male	epididymis	initial segment		
	<u>4353</u>	rat	male	epididymis	initial segment		
KINETWORKS™ SCREEN	<u>4354</u>	rat	male	epididymis	initial segment		
	<u>4355</u>	rat	male	epididymis	initial segment		
ORDER NUMBER	<u>4355</u>	rat	male	epididymis	initial segment		
	<u>4356</u>	rat	male	epididymis	initial segment		
SUMMARY REPORT	<u>4357</u>	rat	male	epididymis	initial segment		
COMPARISON REPORT	<u>4358</u>	rat	male	epididymis	initial segment		
	<u>4358</u>	rat	male	epididymis	initial segment		
PhosphoNET	<u>4359</u>	rat	male	epididymis	initial segment		
	<u>4360</u>	rat	male	epididymis	initial segment		
	<u>4361</u>	rat	male	epididymis	initial segment		
	<u>4361</u>	rat	male	epididymis	initial segment		
	4362	rat	male	epididymis	initial segment		
	4363	rat	male	epididymis	initial segment		
	4364	rat	male	epididymis	initial segment		
	4364	rat	male	epididymis	initial segment		
	4365	rat	male	epididymis	initial segment		
	4366	rat	male	epididymis	initial segment		
	4367	rat	male	epididymis	initial segment		
	4367	rat	male	epididymis	initial segment		
	4368	rat	male	epididymis	initial segment		
	4369	rat	male	epididymis	initial segment		
	<u>4370</u>	rat	male	epididymis	initial segment		
	<u>4370</u>	rat	male	epididymis	initial segment		
	4074		molo	onididumia	initial segment		

Comparison Report

The comparison report is a quantitative list of protein measurements for the order in context. The users can select the normalization group within the order from a drop down menu which will populate the columns with the control and sample values in counts per minute (CPM) for each protein. Next to each sample value is a %CFC (Percent Change From Control) which is simply the control value subtracted from the treatment value, divided by the control value. Generally, the control sample will appear as the first column. Selecting a protein from the list will display its protein profile. *Report column headers: Full name of Protein, Phospho-Epitope, CPM 1,* %CFC 1, CPM 2, %CFC 2, CPM 3, %CFC 3, CPM 4, %CFC 4, CPM 5, %CFC 5.

search by	Order: 711				Screen of Selected Group:						
PROTEIN TARGET	NORMALIZATION GROUP			-	SEAR	сн	KPKS-1.2				
REATMENT			1		2		3		4		5
MODEL SYSTEM	Kinex	aus ID	4358		4355		4364		4367		4352
INETWORKS™ SCREEN	< Full name of Protein	< Phospho Epitope	< CPM 1	« %CFC	1 < CPM :	2 « %CFC :	2 < CPM 3	< %CFC 3	e CPM 4	4 %CFC 4	4 < CPM 5 +
RDER NUMBER	Bone marrow X protein-tyrosine kina		247	0%	312	26%	167	-32%	123	-50%	360
ORDER HOMBER	Calcium/calmodulin-dependent protein		129	0%	138	7%	88	-32%	122	-5%	134
SUMMARY REPORT	Calmodulin-dependent protein-serine		960	0%	984	3%	1,128	18%	1,251	30%	1,158
COMPARISON REPORT	Calmodulin-dependent protein-serine	(81	0%	112	38%	52	-36%	93	15%	92
	CAMP-dependent protein-serine kina:		219	0%	95	-57%	247	13%	290	32%	206
PhosphoNET	Casein protein-serine kinase 1 epsilo		104	0%	96	-8%	100	-4%	88	-15%	115
	Death associated protein kinase 1 (1		222	0%	477	115%	575	159%	403	82%	365
	Extracellular regulated protein-serine		310	0%	274	-12%	277	-11%	231	-25%	346
	Focal adhesion protein-tyrosine kinas		1,794	0%	2,712	51%	3,507	95%	2,481	38%	3,450
	G protein-coupled receptor-serine kin		1,408	0%	2,177	55%	2,077	48%	1,463	4%	2,370
	Inhibitor of NF-kappa-B protein-serine		568	0%	1,408	148%	939	0540	923	63%	1,240
	Janus protein-tyrosine kinase 1		342	0%	395	15%	1,201	251%	1,117	221%	801
	Distain enviro kinese C1 (aCMD den		2 000	0%	4 4 0 2	-23%	040	-10%	495	-3176	1,057
	Protein-serine kinase G1 (CGWP-depi	-	3,233	0%	4,103	2170	1,400	1 70	2,200	-30%	4,043
	Raft proto-oncogene-encoded prote		6 1 25	0%	5,500	10%	6 660	09/	803	-20%	6,602
	Sto proto opcodene encoded protein		57	0%	5,500	-10%	3,333	-3 /0	0,200	E196	01
	Ves-related protein-tyrosine kinase		189	0%	291	54%	167	-12%	262	39%	208

PhosphoNET

PhosphoNET is currently under construction and will be available at a future date.